false Q1 2023--12-31 0000910638 nine months P1Y http://www.3dsystems.com/20230331#RightOfUseAsset http://www.3dsystems.com/20230331#RightOfUseAsset http://www.3dsystems.com/20230331#LeaseLiabilityCurrent http://www.3dsystems.com/20230331#LeaseLiabilityCurrent http://www.3dsystems.com/20230331#LeaseLiabilityNoncurrent http://www.3dsystems.com/20230331#LeaseLiabilityNoncurrent http://www.3dsystems.com/20230331#RightOfUseAsset http://www.3dsystems.com/20230331#RightOfUseAsset http://www.3dsystems.com/20230331#LeaseLiabilityCurrent http://www.3dsystems.com/20230331#RightOfUseAsset http://www.3dsystems.com/20230331#LeaseLiabilityCurrent http://www.3dsystems.com/20230331#LeaseLiabilityNoncurrent http://www.3dsystems.com/20230331#LeaseLiabilityNoncurrent 0.0278364 0.3333 0.3333 0.3333 0000910638 2023-01-01 2023-03-31 0000910638 2023-05-04 xbrli:shares 0000910638 2023-03-31 iso4217:USD 0000910638 2022-12-31 0000910638 ddd:KumovisGmbHMember 2022-12-31 iso4217:USD xbrli:shares 0000910638 us-gaap:ProductMember 2023-01-01 2023-03-31 0000910638 us-gaap:ProductMember 2022-01-01 2022-03-31 0000910638 us-gaap:ServiceMember 2023-01-01 2023-03-31 0000910638 us-gaap:ServiceMember 2022-01-01 2022-03-31 0000910638 2022-01-01 2022-03-31 0000910638 2021-12-31 0000910638 2022-03-31 0000910638 us-gaap:CommonStockMember 2022-12-31 0000910638 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000910638 us-gaap:RetainedEarningsMember 2022-12-31 0000910638 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000910638 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000910638 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000910638 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000910638 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000910638 us-gaap:CommonStockMember 2023-03-31 0000910638 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000910638 us-gaap:RetainedEarningsMember 2023-03-31 0000910638 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000910638 us-gaap:CommonStockMember 2021-12-31 0000910638 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000910638 us-gaap:RetainedEarningsMember 2021-12-31 0000910638 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000910638 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000910638 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000910638 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000910638 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000910638 us-gaap:CommonStockMember 2022-03-31 0000910638 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000910638 us-gaap:RetainedEarningsMember 2022-03-31 0000910638 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000910638 ddd:SaudiArabianIndustrialInvestmentsCompanyMember 2023-03-31 xbrli:pure 0000910638 us-gaap:CorporateJointVentureMember 2023-03-31 0000910638 us-gaap:CorporateJointVentureMember 2022-12-31 0000910638 ddd:DpPolarGmbHMember 2022-10-04 0000910638 ddd:DpPolarGmbHMember 2022-10-04 2022-10-04 0000910638 us-gaap:InProcessResearchAndDevelopmentMember ddd:DpPolarGmbHMember 2022-10-04 0000910638 us-gaap:TradeNamesMember ddd:DpPolarGmbHMember 2022-10-04 0000910638 ddd:KumovisGmbHMember 2022-04-01 0000910638 ddd:KumovisGmbHMember 2022-04-01 2022-04-01 0000910638 ddd:KumovisGmbHMember ddd:KumovisGmbHMember 2022-04-01 0000910638 ddd:ProductTechnologyMember ddd:KumovisGmbHMember 2022-04-01 0000910638 us-gaap:TradeNamesMember ddd:KumovisGmbHMember 2022-04-01 0000910638 ddd:TitanAdditiveLLCMember 2022-04-01 0000910638 ddd:TitanAdditiveLLCMember 2022-04-01 2022-04-01 0000910638 ddd:ProductTechnologyMember ddd:TitanAdditiveLLCMember 2022-04-01 0000910638 us-gaap:TradeNamesMember ddd:TitanAdditiveLLCMember 2022-04-01 0000910638 ddd:SaudiArabianIndustrialInvestmentsCompanyMember 2022-03-31 0000910638 ddd:EntachIncMember 2022-03-31 0000910638 ddd:WuxiEasywayMember 2018-12-31 0000910638 ddd:WuxiEasywayMember 2019-01-21 0000910638 ddd:WuxiEasywayMember 2019-01-21 2019-01-21 0000910638 ddd:WuxiEasywayMember 2022-01-01 2022-03-31 0000910638 2023-04-01 2023-03-31 0000910638 2024-04-01 2023-03-31 0000910638 us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000910638 us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000910638 ddd:OneCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0000910638 ddd:OneCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000910638 srt:AmericasMember 2023-01-01 2023-03-31 0000910638 srt:AmericasMember 2022-01-01 2022-03-31 0000910638 us-gaap:EMEAMember 2023-01-01 2023-03-31 0000910638 us-gaap:EMEAMember 2022-01-01 2022-03-31 0000910638 srt:AsiaPacificMember 2023-01-01 2023-03-31 0000910638 srt:AsiaPacificMember 2022-01-01 2022-03-31 0000910638 country:US 2023-01-01 2023-03-31 0000910638 country:US 2022-01-01 2022-03-31 0000910638 us-gaap:CustomerRelationshipsMember 2023-03-31 0000910638 us-gaap:CustomerRelationshipsMember 2022-12-31 0000910638 ddd:AcquiredTechnologyMember 2023-03-31 0000910638 ddd:AcquiredTechnologyMember 2022-12-31 0000910638 us-gaap:TradeNamesMember 2023-03-31 0000910638 us-gaap:TradeNamesMember 2022-12-31 0000910638 us-gaap:PatentsMember 2023-03-31 0000910638 us-gaap:PatentsMember 2022-12-31 0000910638 us-gaap:PatentedTechnologyMember 2023-03-31 0000910638 us-gaap:PatentedTechnologyMember 2022-12-31 0000910638 us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000910638 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000910638 ddd:HealthcareSegmentMember 2022-12-31 0000910638 ddd:IndustrialSegmentMember 2022-12-31 0000910638 ddd:HealthcareSegmentMember 2023-01-01 2023-03-31 0000910638 ddd:IndustrialSegmentMember 2023-01-01 2023-03-31 0000910638 ddd:HealthcareSegmentMember 2023-03-31 0000910638 ddd:IndustrialSegmentMember 2023-03-31 0000910638 srt:MinimumMember 2023-01-01 2023-03-31 0000910638 srt:MaximumMember 2023-01-01 2023-03-31 utr:sqft 0000910638 us-gaap:ConvertibleDebtMember ddd:ConvertibleSeniorNotesDue2026Member 2021-11-16 0000910638 us-gaap:ConvertibleDebtMember ddd:ConvertibleSeniorNotesDue2026Member 2021-11-16 2021-11-16 0000910638 us-gaap:ConvertibleDebtMember ddd:ConvertibleSeniorNotesDue2026Member 2023-03-31 0000910638 2021-11-16 ddd:day 0000910638 srt:ScenarioForecastMember 2023-04-01 2023-12-31 0000910638 srt:ScenarioForecastMember 2024-01-01 2024-12-31 0000910638 srt:ScenarioForecastMember 2025-01-01 2025-12-31 0000910638 srt:ScenarioForecastMember 2026-01-01 2026-12-31 0000910638 ddd:VolumetricBiotechnologiesIncMember 2021-12-01 0000910638 ddd:VolumetricBiotechnologiesIncMember 2021-12-01 2021-12-01 ddd:milestone 0000910638 us-gaap:PerformanceSharesMember 2021-12-01 0000910638 ddd:VolumetricBiotechnologiesIncMember 2023-01-01 2023-03-31 0000910638 ddd:VolumetricBiotechnologiesIncMember 2022-01-01 2022-03-31 0000910638 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000910638 ddd:IncentiveAwardsMember 2023-01-01 2023-03-31 0000910638 ddd:IncentiveAwardsMember 2022-01-01 2022-03-31 0000910638 ddd:DpPolarGmbHMember 2023-01-01 2023-03-31 0000910638 ddd:DpPolarGmbHMember 2022-01-01 2022-03-31 0000910638 us-gaap:PhantomShareUnitsPSUsMember 2023-01-01 2023-03-31 0000910638 us-gaap:PhantomShareUnitsPSUsMember 2022-01-01 2022-03-31 0000910638 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-03-31 0000910638 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-01-01 2023-03-31 0000910638 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-03-31 0000910638 ddd:RestrictedStockAndRestrictedStockUnitMember 2023-01-01 2023-03-31 0000910638 ddd:RestrictedStockAndRestrictedStockUnitMember 2022-01-01 2022-03-31 0000910638 us-gaap:StockOptionMember 2023-01-01 2023-03-31 0000910638 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0000910638 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000910638 ddd:DpPolarGmbHMember 2023-01-01 2023-03-31 0000910638 ddd:SharesIssuableMember 2023-01-01 2023-03-31 0000910638 us-gaap:SeniorNotesMember ddd:ConvertibleSeniorNotesDue2026Member 2021-11-16 0000910638 us-gaap:SeniorNotesMember ddd:ConvertibleSeniorNotesDue2026Member 2021-11-16 2021-11-16 0000910638 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000910638 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000910638 ddd:AccumulatedUnrealizedLossOnShortTermInvestmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000910638 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000910638 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0000910638 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0000910638 ddd:AccumulatedUnrealizedLossOnShortTermInvestmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0000910638 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000910638 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000910638 ddd:AccumulatedUnrealizedLossOnShortTermInvestmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000910638 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000910638 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000910638 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000910638 ddd:AccumulatedUnrealizedLossOnShortTermInvestmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000910638 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000910638 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-03-31 0000910638 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-03-31 0000910638 ddd:AccumulatedUnrealizedLossOnShortTermInvestmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-03-31 0000910638 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0000910638 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0000910638 ddd:AccumulatedUnrealizedLossOnShortTermInvestmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0000910638 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0000910638 us-gaap:OperatingSegmentsMember ddd:HealthcareSegmentMember 2023-01-01 2023-03-31 0000910638 us-gaap:OperatingSegmentsMember ddd:HealthcareSegmentMember 2022-01-01 2022-03-31 0000910638 ddd:IndustrialSegmentMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000910638 ddd:IndustrialSegmentMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000910638 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000910638 us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000910638 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000910638 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000910638 ddd:ExportControlsAndGovernmentContractsComplianceMember 2020-08-31 ddd:subpoena 0000910638 ddd:ExportControlsAndGovernmentContractsComplianceMember 2023-02-01 2023-02-28 ddd:agency 0000910638 ddd:DirectorateOfDefenseTradeControlsMember ddd:ExportControlsAndGovernmentContractsComplianceMember 2023-02-01 2023-02-28 ddd:installment 0000910638 ddd:BureauOfIndustryAndSecurityOfTheDepartmentOfCommerceMember ddd:ExportControlsAndGovernmentContractsComplianceMember 2023-02-01 2023-02-28 0000910638 ddd:ExportControlsAndGovernmentContractsComplianceMember ddd:USDepartmentOfJusticeMember 2023-02-01 2023-02-28 0000910638 ddd:DirectorateOfDefenseTradeControlsMember ddd:ExportControlsAndGovernmentContractsComplianceMember 2023-01-01 2023-03-31 0000910638 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0000910638 us-gaap:MoneyMarketFundsMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0000910638 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:ShortTermInvestmentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 ddd:ShortTermBondMutualFundMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:CashAndCashEquivalentsMember ddd:ShortTermBondMutualFundMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:ShortTermInvestmentsMember ddd:ShortTermBondMutualFundMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:ShortTermInvestmentsMember us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0000910638 us-gaap:CashAndCashEquivalentsMember 2023-03-31 0000910638 us-gaap:ShortTermInvestmentsMember 2023-03-31 0000910638 us-gaap:AllOtherCorporateBondsMember 2023-03-31 0000910638 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-03-31 0000910638 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0000910638 us-gaap:MoneyMarketFundsMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0000910638 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:ShortTermInvestmentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 ddd:ShortTermBondMutualFundMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:CashAndCashEquivalentsMember ddd:ShortTermBondMutualFundMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:ShortTermInvestmentsMember ddd:ShortTermBondMutualFundMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:CashAndCashEquivalentsMember us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:ShortTermInvestmentsMember us-gaap:AllOtherCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000910638 us-gaap:CashAndCashEquivalentsMember 2022-12-31 0000910638 us-gaap:ShortTermInvestmentsMember 2022-12-31 0000910638 us-gaap:AllOtherCorporateBondsMember 2022-12-31 0000910638 us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0000910638 us-gaap:SubsequentEventMember ddd:WematterABMember 2023-05-01 2023-05-01 0000910638 us-gaap:SubsequentEventMember ddd:WematterABMember 2023-05-01 iso4217:EUR 0000910638 us-gaap:SubsequentEventMember 2023-05-09 2023-05-09 0000910638 srt:MinimumMember us-gaap:SubsequentEventMember 2023-05-09 0000910638 us-gaap:SubsequentEventMember srt:MaximumMember 2023-05-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________to____________
Commission File No. 001-34220
__________________________
3D SYSTEMS CORPORATION
(Exact name of Registrant as Specified in its Charter)
__________________________

Delaware | 95-4431352
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.)

333 Three D Systems Circle
Rock Hill, South Carolina 29730
(Address of Principal Executive Offices and Zip Code)
(Registrant’s Telephone Number, Including Area Code): (803) 326-3900
_________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol |  | Name of each exchange on which registered
Common Stock, par value $0.001 per share |  | DDD |  | New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act .☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Shares of Common Stock, par value $0.001 per share, outstanding as of May 4, 2023: 131,155,200.
1

3D SYSTEMS CORPORATION
Form 10-Q
For the Three Months Ended March 31, 2023
TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION |
Item 1. Financial Statements | 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 39
Item 4. Controls and Procedures | 39
PART II - OTHER INFORMATION |
Item 1. Legal Proceedings | 40
Item 1A. Risk Factors | 40
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 41
Item 3. Defaults Upon Senior Securities | 41
Item 4. Mine Safety Disclosures | 41
Item 5. Other Information | 41
Item 6. Exhibits | 41

2

PART I — FINANCIAL INFORMATION
Item 1. Financial Statements.
3D SYSTEMS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

(in thousands, except par value) | March 31, 2023 |  | December 31, 2022
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 525,898 |  |  | $ | 388,134 |
Short-term investments | 4,027 |  |  | 180,603 |
Accounts receivable, net of reserves — $2,922 and $3,114 | 94,677 |  |  | 93,886 |
Inventories | 147,365 |  |  | 137,832 |
Prepaid expenses and other current assets | 38,242 |  |  | 33,790 |
Total current assets | 810,209 |  |  | 834,245 |
Property and equipment, net | 62,150 |  |  | 58,072 |
Intangible assets, net | 88,064 |  |  | 90,230 |
Goodwill | 385,754 |  |  | 385,312 |
Right-of-use assets | 57,090 |  |  | 42,746 |
Deferred income tax asset | 7,214 |  |  | 7,038 |
Other assets | 31,813 |  |  | 28,970 |
Total assets | $ | 1,442,294 |  |  | $ | 1,446,613 |
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY |  |  |
Current liabilities: |  |  |
Current lease liabilities | $ | 10,542 |  |  | $ | 9,036 |
Accounts payable | 51,415 |  |  | 53,826 |
Accrued and other liabilities | 54,159 |  |  | 55,571 |
Customer deposits | 6,321 |  |  | 6,911 |
Deferred revenue | 31,575 |  |  | 26,464 |
Total current liabilities | 154,012 |  |  | 151,808 |
Long-term debt, net of deferred financing costs | 450,179 |  |  | 449,510 |
Long-term lease liabilities | 55,231 |  |  | 41,779 |
Deferred income tax liability | 7,680 |  |  | 7,631 |
Other liabilities | 43,744 |  |  | 44,181 |
Total liabilities | 710,846 |  |  | 694,909 |
Commitments and contingencies (Note 17) |  |  |
Redeemable non-controlling interest | 1,762 |  |  | 1,760 |
Stockholders’ equity: |  |  |
Common stock, $0.001 par value, authorized 220,000 shares; shares issued 131,164 and 131,207 as of March 31, 2023 and December 31, 2022, respectively | 131 |  |  | 131 |
Additional paid-in capital | 1,553,038 |  |  | 1,547,597 |
Accumulated deficit | (773,383) |  |  | (743,962) |
Accumulated other comprehensive loss | (50,100) |  |  | (53,822) |
Total stockholders’ equity | 729,686 |  |  | 749,944 |
Total liabilities, redeemable non-controlling interest and stockholders’ equity | $ | 1,442,294 |  |  | $ | 1,446,613 |

See accompanying notes to condensed consolidated financial statements.
3

3D SYSTEMS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

| Three Months Ended |  |
(in thousands, except per share amounts) | March 31, 2023 |  | March 31, 2022 |  |  |  |
Revenue: |  |  |  |  |  |  |
Products | $ | 84,388 |  |  | $ | 100,551 |  |  |  |  |
Services | 36,848 |  |  | 32,450 |  |  |  |  |
Total revenue | 121,236 |  |  | 133,001 |  |  |  |  |
Cost of sales: |  |  |  |  |  |  |
Products | 49,880 |  |  | 58,472 |  |  |  |  |
Services | 24,258 |  |  | 20,734 |  |  |  |  |
Total cost of sales | 74,138 |  |  | 79,206 |  |  |  |  |
Gross profit | 47,098 |  |  | 53,795 |  |  |  |  |
Operating expenses: |  |  |  |  |  |  |
Selling, general and administrative | 58,285 |  |  | 55,415 |  |  |  |  |
Research and development | 22,209 |  |  | 21,612 |  |  |  |  |
Total operating expenses | 80,494 |  |  | 77,027 |  |  |  |  |
Loss from operations | (33,396) |  |  | (23,232) |  |  |  |  |
Interest and other income (expense), net | 3,875 |  |  | (2,283) |  |  |  |  |
(Loss) income before income taxes | (29,521) |  |  | (25,515) |  |  |  |  |
(Provision) benefit for income taxes | (8) |  |  | (1,284) |  |  |  |  |
Net (loss) income before redeemable non-controlling interest | (29,529) |  |  | (26,799) |  |  |  |  |
Less: net (loss) attributable to redeemable non-controlling interest | (108) |  |  | — |  |  |  |  |
Net (loss) income attributable to 3D Systems Corporation | $ | (29,421) |  |  | $ | (26,799) |  |  |  |  |
Net (loss) income per common share: |  |  |  |  |  |  |
Basic | $ | (0.23) |  |  | $ | (0.21) |  |  |  |  |
Diluted | $ | (0.23) |  |  | $ | (0.21) |  |  |  |  |
Weighted average shares outstanding: |  |  |  |  |  |  |
Basic | 129,158 |  |  | 126,728 |  |  |  |  |
Diluted | 129,158 |  |  | 126,728 |  |  |  |  |

See accompanying notes to condensed consolidated financial statements.
4

3D SYSTEMS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(Unaudited)

| Three Months Ended
(in thousands) | March 31, 2023 |  | March 31, 2022 |  |
Net (loss) income before redeemable non-controlling interest | $ | (29,529) |  |  | $ | (26,799) |  |  |
Other comprehensive (loss) income, net of taxes: |  |  |  |  |
Pension plan adjustments | — |  |  | 101 |  |  |
Foreign currency translation | 3,413 |  |  | (3,346) |  |  |
Unrealized (loss) income on short-term investments | 309 |  |  | (3,495) |  |  |
Total other comprehensive (loss) income, net of taxes: | 3,722 |  |  | (6,740) |  |  |
Total comprehensive (loss) income, net of taxes | (25,807) |  |  | (33,539) |  |  |
Less: comprehensive loss attributable to redeemable non-controlling interest | (108) |  |  | — |  |  |
Comprehensive (loss) income attributable to 3D Systems Corporation | $ | (25,699) |  |  | $ | (33,539) |  |  |

See accompanying notes to condensed consolidated financial statements.
5

3D SYSTEMS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| Three Months Ended
(in thousands) | March 31, 2023 |  | March 31, 2022 |  |
Cash flows from operating activities: |  |  |  |  |
Net (loss) income before redeemable non-controlling interest | $ | (29,529) |  |  | $ | (26,799) |  |  |
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: |  |  |  |  |
Depreciation, amortization and accretion of debt discount | 9,220 |  |  | 9,147 |  |  |
Stock-based compensation | 10,292 |  |  | 12,658 |  |  |
Unrealized gain on exchange rate | — |  |  | (439) |  |  |
Loss on short-term investments | 29 |  |  | — |  |  |
Non-cash operating lease expense | 1,903 |  |  | 1,709 |  |  |
Provision for inventory obsolescence and revaluation | 2,926 |  |  | (517) |  |  |
Provision for bad debts | 13 |  |  | 1,076 |  |  |
Loss (gain) on the disposition of businesses, property, equipment and other assets | 423 |  |  | 137 |  |  |
Benefit for deferred income taxes and reserve adjustments | (259) |  |  | 466 |  |  |
Asset impairment | — |  |  | 40 |  |  |
Changes in operating accounts: |  |  |  |  |
Accounts receivable | (208) |  |  | 3,173 |  |  |
Inventories | (12,327) |  |  | (8,822) |  |  |
Prepaid expenses and other current assets | (4,146) |  |  | 2,225 |  |  |
Accounts payable | (2,947) |  |  | 277 |  |  |
Deferred revenue and customer deposits | 3,120 |  |  | 1,901 |  |  |
Accrued and other liabilities | (6,994) |  |  | (8,679) |  |  |
All other operating activities | 762 |  |  | (2,678) |  |  |
Net cash (used in) provided by operating activities | (27,722) |  |  | (15,125) |  |  |
Cash flows from investing activities: |  |  |  |  |
Purchases of property and equipment | (9,027) |  |  | (4,079) |  |  |
Purchases of short-term investments | — |  |  | (366,005) |  |  |
Sales and maturities of short-term investments | 176,856 |  |  | 6,170 |  |  |
Acquisitions and other investments, net of cash acquired | — |  |  | (9,335) |  |  |
Other investing activities | — |  |  | 40 |  |  |
Net cash provided by (used in) investing activities | 167,829 |  |  | (373,209) |  |  |
Cash flows from financing activities: |  |  |  |  |
Purchase of non-controlling interests | — |  |  | (2,300) |  |  |
Taxes paid related to net-share settlement of equity awards | (2,115) |  |  | (10,052) |  |  |
Other financing activities | (179) |  |  | (166) |  |  |
Net cash (used in) provided by financing activities | (2,294) |  |  | (12,518) |  |  |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 114 |  |  | 464 |  |  |
Net (decrease) increase in cash, cash equivalents and restricted cash | 137,927 |  |  | (400,388) |  |  |
Cash, cash equivalents and restricted cash at the beginning of the year (a) | 391,975 |  |  | 789,970 |  |  |
Cash, cash equivalents and restricted cash at the end of the period (a) | $ | 529,902 |  |  | $ | 389,582 |  |  |

6

Supplemental cash flow information |  |  |  |  |
Lease assets obtained in exchange for new lease liabilities | $ | 16,318 |  |  | $ | 1,922 |  |  |
Cash interest payments | 48 |  |  | 55 |  |  |
Cash income tax payments, net | 1,549 |  |  | 8,496 |  |  |
Transfer of equipment from inventory to property and equipment, net (b) | 735 |  |  | 21 |  |  |

(a) The amounts for cash and cash equivalents shown above include restricted cash of $115 and $114 as of March 31, 2023 and December 31, 2022, respectively, which are included in prepaid expenses and other current assets. In addition, included in cash and cash equivalents above as of March 31, 2023 and December 31, 2022 is $3,889 and $3,727, respectively, of restricted cash, which, is included in other non-current assets. The amounts for cash and cash equivalents shown above include restricted cash of $312 as of March 31, 2022, and December 31, 2021.
(b)Inventory is transferred to property and equipment at cost when we require additional machines for training or demonstration or for placement into on demand manufacturing services locations.
See accompanying notes to condensed consolidated financial statements.
7

3D SYSTEMS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Three Months Ended March 31, 2023 and 2022
(Unaudited)

| Common Stock |  |  |  |  |  |  |  |  |  |  |
(in thousands, except par value) | Shares |  | Par Value $0.001 |  | Additional Paid-In Capital |  |  | Accumulated Deficit |  | Accumulated Other Comprehensive Income (Loss) |  |  |  | Total Stockholders' Equity
December 31, 2022 | 131,207 |  |  | $ | 131 |  |  | $ | 1,547,597 |  |  |  | $ | (743,962) |  |  | $ | (53,822) |  |  |  |  | $ | 749,944 |
Shares issued, vested & expired under equity incentive plans | 165 |  |  | — |  |  | — |  |  |  | — |  |  | — |  |  |  |  | — |
Shares withheld related to net-share settlement of equity awards | (208) |  |  | — |  |  | (2,115) |  |  |  | — |  |  | — |  |  |  |  | (2,115) |
Stock-based compensation expense | — |  |  | — |  |  | 7,644 |  |  |  | — |  |  | — |  |  |  |  | 7,644 |
Net (loss) attributable to 3D Systems Corp. | — |  |  | — |  |  | — |  |  |  | (29,421) |  |  | — |  |  |  |  | (29,421) |
Unrealized loss on short-term investments | — |  |  | — |  |  | — |  |  |  | — |  |  | 309 |  |  |  |  | 309 |
Redeemable non-controlling interest redemption value in excess of carrying value | — |  |  | — |  |  | (88) |  |  |  | — |  |  | — |  |  |  |  | (88) |
Foreign currency translation adjustment | — |  |  | — |  |  | — |  |  |  | — |  |  | 3,413 |  |  |  |  | 3,413 |
March 31, 2023 | 131,164 |  |  | $ | 131 |  |  | $ | 1,553,038 |  |  |  | $ | (773,383) |  |  | $ | (50,100) |  |  |  |  | $ | 729,686 |
December 31, 2021 | 128,375 |  |  | $ | 128 |  |  | $ | 1,501,210 |  |  |  | $ | (621,251) |  |  | $ | (37,706) |  |  |  |  | $ | 842,381 |
Issuance (repurchase) of stock | 1,991 |  |  | 2 |  |  | (8,696) |  |  |  | — |  |  | — |  |  |  |  | (8,694) |
Stock-based compensation expense | — |  |  | — |  |  | 26,728 |  |  |  | — |  |  | — |  |  |  |  | 26,728 |
Net loss | — |  |  | — |  |  | — |  |  |  | (26,799) |  |  | — |  |  |  |  | (26,799) |
Pension adjustment | — |  |  | — |  |  | — |  |  |  | — |  |  | 101 |  |  |  |  | 101 |
Unrealized loss on short-term investments |  |  |  |  |  |  |  |  |  | (3,495) |  |  |  |  | (3,495) |
Foreign currency translation adjustment |  |  |  |  |  |  |  |  |  | (3,346) |  |  |  |  | (3,346) |
March 31, 2022 | 130,366 |  |  | $ | 130 |  |  | $ | 1,519,242 |  |  |  | $ | (648,050) |  |  | $ | (44,446) |  |  |  |  | $ | 826,876 |

See accompanying notes to condensed consolidated financial statements.
8

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of 3D Systems Corporation and all majority and wholly-owned subsidiaries and entities in which a controlling interest is maintained (“3D Systems” or the “Company” or “we” or “our” or “us”). All significant intercompany accounts and transactions have been eliminated in consolidation.
A non-controlling interest in a subsidiary is considered an ownership interest in a majority-owned subsidiary that is not attributable to the parent. For the periods presented, the Company's financial statements include a redeemable non-controlling interest (“RNCI”), which has been reported in temporary equity in the consolidated balance sheets. The net income (loss) attributable to the RNCI is presented as an adjustment to the Company's consolidated net income (loss) to arrive at net income (loss) attributable to 3D Systems Corporation in the consolidated statements of operations and consolidated statements of comprehensive income (loss). Furthermore, adjustments to record the RNCI at its redemption value are recorded to additional paid-in capital, and the excess redemption value is recognized as a reduction to the net income, or increase to the net loss, attributable to 3D Systems’ shareholders for purposes of reporting earnings or loss per share. See Note 10.
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”). The Company believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading. In the opinion of management, the unaudited condensed consolidated financial statements contain all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the financial position, results of operations, and cash flows for the periods presented. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions.
Our annual reporting period is the calendar year. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year. All dollar amounts and other amounts presented in the accompanying footnotes are presented in thousands, except for per share information.
Summary of Significant Accounting Policies
Equity Securities without a Readily Determinable Value
We recognize investments in equity securities without a readily determinable fair value at cost minus impairment. We assess these investments for potential impairment if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment charges taken with respect to these investments are recorded to interest and other income (expense), net in the consolidated statements of operations in the period in which an investment becomes impaired. No impairment charges were recorded during the three months ended March 31, 2023 or 2022. The aggregate carrying value of the Company’s equity investments without a readily determinable value was $13,162 and $13,153 at March 31, 2023 and December 31, 2022, respectively, and is included in other assets on our consolidated balance sheets.
Equity Method of Accounting
During the three months ended March 31, 2023, the formation of the joint venture between the Company and the Saudi Arabian Industrial Investments Company (“Dussur”) was completed, and the Company became a shareholder with a 49% ownership interest. See Note 2. The Company will account for its investment in the joint venture using the equity method of accounting because it does not have a controlling interest and is not the primary beneficiary; however, the Company has the ability to exert significant influence. Under the equity method of accounting, the initial investment is recorded at cost, and the investment is subsequently adjusted for the Company’s proportionate share of the net earnings or losses and other comprehensive income of the investee. Intercompany profits or losses associated with the Company’s equity method investments are eliminated until realized by the investee in transactions with third parties. The carrying value of the investment is recorded as other assets in the Company’s consolidated balance sheets. Income or loss from this investment will be recorded as a separate line item in the consolidated statements of operations on a three-month lag. We evaluate material events occurring during the three-month lag to determine whether the effects of such events should be disclosed in our financial statements. The Company will evaluate its investment in the joint venture for impairment whenever events or changes in circumstances indicate that the carrying amount
9

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
of the investment may not be recoverable. The Company has accounts receivable balances due from the joint venture of $1,177 and $2,247 as of March 31, 2023 and December 31, 2022, respectively, primarily related to the Company's sales of inventory and equipment to the joint venture prior to the Company becoming a shareholder.
Other Accounting Policy Updates
All other significant accounting policies described in the 2022 Form 10-K remain unchanged.
(2) Acquisitions
dp polar
On October 4, 2022, we completed the acquisition of 100% of dp polar GmbH (“dp polar”), a German-based designer and manufacturer of the industry’s first additive manufacturing system designed for true high-speed mass production of customized components, for $25,201 (including customary post-closing adjustments), which includes $19,604 paid in cash at closing, $7,091 paid at closing via the issuance of the Company’s common stock, and a provisional $1,494 estimated post-closing purchase price adjustment due to the Company from the sellers. See Note 11 for discussion of an earnout arrangement with a key individual from dp polar.
The Company acquired dp polar for access to dp polar's patented continuous printing process. This business and its technology are expected to contribute to the operations of the Company's Healthcare Solutions and Industrial Solutions segments. Central to dp polar’s patented continuous printing process is a large-scale, segmented, rotating print platform that eliminates the start/stop operations of virtually all additive manufacturing platforms. With dp polar’s technology and patented polar coordinate control, the print heads remain stationary above the rotating platform, providing a continuous print process.
We accounted for the acquisition of dp polar using the acquisition method, as prescribed by ASC 805, “Business Combinations” (“ASC 805”). In accordance with valuation methodologies described in ASC 820, “Fair Value Measurement” (“ASC 820”), the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the dp polar acquisition. Shown below is the preliminary purchase price allocation, which summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition:

(in thousands) |  |  |  |
Current assets, including cash acquired of $243 |  |  |  | $ | 301 |
Intangible assets: |  |  |  |
In-process research and development |  | $ | 4,989 |  |  |
Trade name |  | 3,930 |  |  |
Total intangible assets |  |  |  | 8,919 |
Goodwill |  |  |  | 13,969 |
Other assets |  |  |  | 2,376 |
Liabilities: |  |  |  |
Accounts payable and accrued liabilities |  | $ | 364 |  |  |
Total liabilities |  |  |  | 364 |
Net assets acquired |  |  |  | $ | 25,201 |

The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and dp polar’s assembled workforce. This goodwill is not expected to be deductible for tax purposes.
As of March 31, 2023, the purchase price allocation for dp polar is preliminary. The Company continues to review the final closing balance sheet of dp polar and may further adjust the acquisition-date fair values of acquired assets and assumed liabilities based on this review. The Company also continues to review dp polar’s pre-acquisition tax returns to determine the final tax positions, including net operating losses and any required valuation allowance. The final purchase price allocations will be completed when the Company has finished its valuation activities and the review of dp polar’s closing balance sheet and the pre-acquisition tax returns. These final allocations could differ materially from the current preliminary allocations. The final
10

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
allocations may include (1) changes in the preliminary allocations to acquired intangible assets and goodwill and (2) changes in the preliminary allocations to other assets and liabilities, including but not limited to tax assets and liabilities, inclusive of deferred taxes. The estimated useful lives of acquired intangible assets are also preliminary.
Kumovis
On April 1, 2022, we completed the acquisition of 93.75% of Kumovis GmbH (“Kumovis”) for an all-cash purchase price of $37,875 (including customary post-closing adjustments), plus an estimated RNCI of $1,559. $3,628 of the cash payment is deferred for up to fifteen months from the closing date. Kumovis, which is part of the Healthcare Solutions segment and reporting unit, utilizes polyether ether keton or “PEEK” materials, which has properties that lend it to many medical applications that fit into our personalized healthcare solutions operations, including many implant applications.
In conjunction with the Kumovis acquisition, the Company and the non-controlling shareholders entered into a put/call option agreement, whereby, at a later date, the Company has the option to purchase from the non-controlling shareholders, and the non-controlling shareholders have the option to sell to the Company, the remaining 6.25% ownership interest in Kumovis for an exercise price calculated based on the achievement of pre-determined revenue and gross profit targets. Fifty percent of the Kumovis common shares related to the put/call can be exercised upon the achievement of an initial revenue and gross profit target, while the remaining 50% can be exercised upon the achievement of a second revenue and gross profit target. If one or both sets of targets have not been met within 5.75 years from the acquisition date, there is a floor strike price that must be exercised. Up to 50% of the exercise price can be paid in Company common stock at the election of 3D Systems. This arrangement results in the recognition of RNCI, for which an estimated fair value of $1,559 was recorded as of the acquisition date.
We accounted for the acquisition of Kumovis using the acquisition method, as prescribed by ASC 805, and we have completed the allocation of the final purchase price. In accordance with valuation methodologies described in ASC 820, the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the Kumovis acquisition. The table below reflects the fair value of both the consideration transferred and the RNCI attributable to this acquisition:

(in thousands) |
Cash paid at acquisition | $ | 34,098 |
Deferred cash consideration | 3,628 |
Estimated fair value of RNCI | 1,559 |
Post-closing net working capital adjustment | 149 |
Total fair value of consideration transferred | $ | 39,434 |

Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed at the date of acquisition:
11

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(in thousands) |  |  |  |
Current assets, including cash acquired of $125 |  |  |  | $ | 1,407 |
Intangible assets: |  |  |  |
Product technology |  | $ | 20,770 |  |  |
Trade name |  | 5,802 |  |  |
Total intangible assets |  |  |  | 26,572 |
Goodwill |  |  |  | 17,618 |
Other assets |  |  |  | 705 |
Liabilities: |  |  |  |
Accounts payable and accrued liabilities |  | $ | 332 |  |  |
Deferred revenue |  | 70 |  |  |
Deferred tax liability |  | 6,466 |  |  |
Total liabilities |  |  |  | 6,868 |
Net assets acquired |  |  |  | $ | 39,434 |

The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Kumovis’s assembled workforce. This goodwill is not expected to be deductible for tax purposes.
Titan
On April 1, 2022, we completed the acquisition of 100% of Titan Additive LLC (“Titan”) for an all-cash purchase price of $39,040. Titan, which is part of the Industrial Solutions segment and reporting unit, is a pellet-based extrusion platform that addresses customer applications requiring large build volumes, superior performance, and improved productivity at significantly lower cost. We believe the acquisition of Titan will open up new markets in the Industrial Solutions segment.
We accounted for the acquisition of Titan using the acquisition method, as prescribed by ASC 805, and we have completed the allocation of the purchase price. Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed, as determined at the date of acquisition in accordance with valuation methodologies described in ASC 820:

(in thousands) |  |  |  |
Current assets |  |  |  | $ | 661 |
Intangible assets: |  |  |  |
Product technology |  | $ | 15,940 |  |  |
Trade name |  | 5,580 |  |  |
Total intangible assets |  |  |  | 21,520 |
Goodwill |  |  |  | 17,430 |
Other assets |  |  |  | 68 |
Liabilities: |  |  |  |
Accounts payable and accrued liabilities |  | $ | 229 |  |  |
Deferred revenue |  | 410 |  |  |
Total liabilities |  |  |  | 639 |
Net assets acquired |  |  |  | $ | 39,040 |

The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Titan’s assembled workforce. This goodwill is expected to be deductible for tax purposes.
12

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Dussur
In March 2022, we and Dussur signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia’s domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. 3D Systems is committed to an initial investment of approximately $6,500, of which $3,435 was deposited in an escrow account during the three months ended December 31, 2022 and is reported as restricted cash within other assets on the balance sheet as of March 31, 2023 and December 31, 2022. In February 2023, the Company became a shareholder in the joint venture and now owns 49% of its common stock. Accordingly, the $3,435 held in escrow plus an additional approximately $3,065 owed to the joint venture as of March 31, 2023 was deposited into a bank account of the joint venture during April 2023 for use in its operations. Additional future investments are contingent upon achievement of certain milestones by the joint venture. The impact on the Company’s financial position, results of operations and cash flows is not expected to be material other than the cash outflow(s) related to the initial and contingent investments.
Enhatch
In March 2022, we made a $10,000 investment in convertible preferred shares for an approximate 26.6% ownership interest in Enhatch Inc. (“Enhatch”), the developer of the Intelligent Surgery Ecosystem. We simultaneously entered into a supply agreement with Enhatch. We also obtained warrants to purchase additional shares of Enhatch, as well as the right to purchase in the future (“call option”) the remaining shares of Enhatch that 3D Systems does not own if certain revenue targets are achieved. The investment, including the embedded call option and the warrants, is recorded in other assets on the consolidated balance sheet.
Enhatch’s Intelligent Surgery Ecosystem provides technologies which streamline and scale the design and delivery of patient-specific medical devices by automating the process. Incorporating these capabilities into 3D Systems’ workflow for patient-specific solutions, which includes advanced software, expert treatment planning services, custom implants and instrumentation design, and industry-leading production processes, will help more efficiently meet the growing demand for personalized medical devices.
Acquisitions of Non-controlling Interests
As of December 31, 2018, the Company owned approximately 70% of the capital and voting rights of Easyway, a service bureau and distributor of 3D printing and scanning products in China. The remaining 30% of the capital and voting rights of Easyway were acquired on January 21, 2019 for $13,500, which has been paid in installments. The Company made the final installment payment of $2,300 related to the acquisition of the remaining 30% interest in Easyway during the three months ended March 31, 2022.
(3) Revenue
Revenue is recognized when control of the promised products or services is transferred to customers.
Performance Obligations
At March 31, 2023, we had $81,214 of outstanding performance obligations, comprised of deferred revenue, customer order backlog and customer deposits. We expect to recognize approximately 87.7% of the $41,648 of deferred revenue and customer deposits as revenue within the next twelve months, an additional 9.0% by the end of 2024 and the remaining balance thereafter.
13

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Collaboration and Licensing Agreements
We enter into collaboration and licensing agreements with third parties. The nature of the activities to be performed and the consideration exchanged under the agreements varies on a contract-by-contract basis. We evaluate these agreements to determine whether they meet the definition of a customer relationship for which revenue is recorded. These contracts may contain multiple performance obligations and may contain fees for licensing, research and development services, contingent milestone payments upon the achievement of developmental contractual criteria and/or royalty fees based on the licensees’ product revenue. We determine the revenue to be recognized for these agreements based on an evaluation of the distinct performance obligations, the identification and evaluation of material rights, the estimation of variable consideration and the determination of the pattern of transfer of control for each distinct performance obligation. The Company recognized $4,740 and $2,432 in revenue related to collaboration arrangements with customers for the three months ended March 31, 2023 and 2022, respectively.
Contract Balances
During the three months ended March 31, 2023, we recognized revenue of $12,832 related to our contract liabilities at December 31, 2022. During the three months ended March 31, 2022, we recognized revenue of $11,895 related to our contract liabilities at December 31, 2021.
Revenue Concentrations
For the three months ended March 31, 2023 and 2022, one customer accounted for approximately 13.5% and 26.7% of our consolidated revenue, respectively. We expect to maintain our relationship with this customer.
Revenue by geographic region for the three months ended March 31, 2023 and 2022 was as follows:

| Three Months Ended
(in thousands) | March 31, 2023 |  | March 31, 2022 |  |
Americas | $ | 68,649 |  |  | $ | 74,249 |  |  |
EMEA | 42,810 |  |  | 40,940 |  |  |
APAC | 9,777 |  |  | 17,812 |  |  |
Total | $ | 121,236 |  |  | $ | 133,001 |  |  |
United States (included in Americas above) | $ | 67,783 |  |  | $ | 73,620 |  |  |

(4) Inventories
Components of inventories at March 31, 2023 and December 31, 2022 are summarized as follows:

(in thousands) | March 31, 2023 |  | December 31, 2022
Raw materials | $ | 57,320 |  |  | $ | 59,907 |
Work in process | 5,778 |  |  | 4,972 |
Finished goods and parts | 84,267 |  |  | 72,953 |
Total inventories | $ | 147,365 |  |  | $ | 137,832 |

The inventory reserve w as $16,641 and $15,550 as of March 31, 2023 and December 31, 2022, respectively.
14

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(5) Intangible Assets
At March 31, 2023 and December 31, 2022, the Company's intangible assets with finite lives were as follows:

| March 31, 2023 |  | December 31, 2022
(in thousands) | Gross |  | Accumulated Amortization |  | Net |  | Gross |  | Accumulated Amortization |  | Net
Intangible assets with finite lives: |  |  |  |  |  |  |  |  |  |  |
Customer relationships | $ | 51,677 |  |  | $ | (49,608) |  |  | $ | 2,069 |  |  | $ | 51,137 |  |  | $ | (48,695) |  |  | $ | 2,442 |
Acquired technology | 55,918 |  |  | (12,421) |  |  | 43,497 |  |  | 55,480 |  |  | (10,707) |  |  | 44,773 |
Trade names | 36,194 |  |  | (13,248) |  |  | 22,946 |  |  | 35,930 |  |  | (12,455) |  |  | 23,475 |
Patent costs | 18,873 |  |  | (10,995) |  |  | 7,878 |  |  | 18,673 |  |  | (10,909) |  |  | 7,764 |
Acquired patents | 17,513 |  |  | (15,730) |  |  | 1,783 |  |  | 17,499 |  |  | (15,661) |  |  | 1,838 |
Other | 13,258 |  |  | (8,905) |  |  | 4,353 |  |  | 13,255 |  |  | (8,765) |  |  | 4,490 |
Total intangible assets | $ | 193,433 |  |  | $ | (110,907) |  |  | $ | 82,526 |  |  | $ | 191,974 |  |  | $ | (107,192) |  |  | $ | 84,782 |

The Company’s total intangible assets reported on the balance sheet include an indefinite-life intangible asset related to dp polar intellectual property research and development (“IPR&D”). The carrying value of this indefinite-lived intangible asset was $5,538 and $5,448 as of March 31, 2023 and December 31, 2022.
Amortization expense related to intangible assets was $3,239 a nd $2,678 for the three months ended March 31, 2023 and 2022, respectively. Amortization expense for intangible assets is estimated to be $7,935 for the remainder of 2023, $11,146 in 2024, $11,112 in 2025, $9,268 in 2026 and $7,419 in 2027.
(6) Goodwill
The following table reflects the changes in the carrying amount of goodwill by reporting unit for the three months ended March 31, 2023:

| Three Months Ended March 31, 2023
| Healthcare |  | Industrial |  | Consolidated
(in thousands) | Gross Goodwill |  | Impairments |  | Net Goodwill |  | Gross Goodwill |  | Impairments |  | Net Goodwill |  | Gross Goodwill |  | Impairments |  | Net Goodwill
Balance at beginning of year | $ | 143,431 |  |  | $ | (32,055) |  |  | $ | 111,376 |  |  | $ | 316,265 |  |  | $ | (42,329) |  |  | $ | 273,936 |  |  | $ | 459,696 |  |  | $ | (74,384) |  |  | $ | 385,312 |
Measurement period adjustments | (555) |  |  | — |  |  | (555) |  |  | (703) |  |  | — |  |  | (703) |  |  | (1,258) |  |  | — |  |  | (1,258) |
Foreign currency translation adjustments | 733 |  |  | — |  |  | 733 |  |  | 967 |  |  | — |  |  | 967 |  |  | 1,700 |  |  | — |  |  | 1,700 |
Balance at end of period | $ | 143,609 |  |  | $ | (32,055) |  |  | $ | 111,554 |  |  | $ | 316,529 |  |  | $ | (42,329) |  |  | $ | 274,200 |  |  | $ | 460,138 |  |  | $ | (74,384) |  |  | $ | 385,754 |

The effect of foreign currency exchange in the table above reflects the impact on goodwill of amounts recorded in currencies other than the U.S. dollar in the financial statements of foreign subsidiaries and the resulting effect of foreign currency translation between the applicable functional currency and the U.S. dollar.
(7) Leases
We have various lease agreements for our facilities, equipment and vehicles with remaining lease terms ranging from one to fifteen years. During the three months ended March 31, 2023, a new 100,000 square foot building that was previously being constructed adjacent to our corporate office became available for use by the Company. As a result, the lease was deemed to have commenced during the period. The total estimated base rent lease payments commenced prior to occupancy in December of 2022. As of March 31, 2023, the remaining minimum base lease payments total $18,861 and consist of $845, $1,143, $1,160, $1,178, $1,196, and $13,339 due, respectively, during the years ended December 31, 2023, 2024, 2025, 2026, 2027 and thereafter.
Classifications of the lease amounts reported on our balance sheet as of March 31, 2023 and December 31, 2022 are
15

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
summarized below:

|  | March 31, 2023 |  | December 31, 2022
(in thousands) |  | Right-of-use assets |  | Current lease liabilities |  | Long-term lease liabilities |  | Right-of-use assets |  | Current lease liabilities |  | Long-term lease liabilities
Operating leases |  | $ | 53,924 |  |  | $ | 9,838 |  |  | $ | 52,035 |  |  | $ | 39,502 |  |  | $ | 8,343 |  |  | $ | 38,499 |
Finance leases |  | 3,166 |  |  | 704 |  |  | 3,196 |  |  | 3,244 |  |  | 693 |  |  | 3,280 |
Total |  | $ | 57,090 |  |  | $ | 10,542 |  |  | $ | 55,231 |  |  | $ | 42,746 |  |  | $ | 9,036 |  |  | $ | 41,779 |

(8) Accrued and Other Liabilities
Accrued liabilities at March 31, 2023 and December 31, 2022 are summarized as follows:

(in thousands) | March 31, 2023 |  | December 31, 2022
Compensation and benefits | $ | 23,364 |  |  | $ | 19,814 |
Accrued taxes | 7,605 |  |  | 10,694 |
Legal contingencies | 4,774 |  |  | 9,948 |
Product warranty liability | 2,812 |  |  | 3,677 |
Other accrued liabilities | 15,604 |  |  | 11,438 |
Total | $ | 54,159 |  |  | $ | 55,571 |

Other liabilities at March 31, 2023 and December 31, 2022 are summarized as follows:

(in thousands) | March 31, 2023 |  | December 31, 2022
Long-term employee indemnity | $ | 4,759 |  |  | $ | 4,817 |
Long-term tax liability | 5,797 |  |  | 5,711 |
Defined benefit pension obligation | 5,124 |  |  | 5,050 |
Long-term deferred revenue | 3,752 |  |  | 4,974 |
Earnout liability | 21,224 |  |  | 17,244 |
Legal contingencies | 2,789 |  |  | 6,096 |
Other long-term liabilities | 299 |  |  | 289 |
Total | $ | 43,744 |  |  | $ | 44,181 |

Changes in the product warranty obligation for the three months ended March 31, 2023 and 2022 are summarized below:

(in thousands) |  | Beginning Balance |  | Settlements Made |  | Accruals for Warranties Issued |  | Ending Balance
March 31, 2023 |  | $ | 3,677 |  |  | $ | (561) |  |  | $ | (304) |  |  | $ | 2,812 |
March 31, 2022 |  | $ | 3,585 |  |  | $ | (2,254) |  |  | $ | 2,245 |  |  | $ | 3,576 |

16

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(9) Borrowings
Convertible Notes
On November 16, 2021, the Company issued $460,000 in aggregate principal amount of 0% Convertible Senior Notes due November 15, 2026 (the “Notes”), pursuant to an Indenture dated November 16, 2021 (the “Indenture”) between the Company and The Bank of New York Mellon, N.A., as trustee. The net proceeds from the offering of the Notes were $446,534 after deducting the initial purchasers’ discounts and commissions and offering expenses payable by the Company in the amount of $13,466, of which $9,821 is unamortized at March 31, 2023. The annual effective interest rate of the Notes is 0.594% when including purchasers' discounts and commissions and offering expenses incurred by the Company. The Notes are senior, unsecured obligations of the Company, will not bear regular interest, and the principal amount of the Notes will not accrete. The Notes will mature on November 15, 2026, unless earlier redeemed, repurchased or converted in accordance with their terms. The Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding August 15, 2026, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2022 (and only during such quarter), if the last reported sale price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), is equal to or greater than 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Common Stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; and (4) upon the occurrence of specified corporate events, including a Fundamental Change (as defined in the Indenture), or distributions of the Common Stock. On or after August 15, 2026, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, at the option of the holder, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of Common Stock, or a combination of cash and shares of Common Stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Notes have an initial conversion rate of 27.8364 shares of Common Stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the Indenture. Holders of the Notes have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid special interest, upon the occurrence of a Fundamental Change. The Company is also required to increase the conversion rate for holders who convert their Notes in connection with a Fundamental Change or convert their Notes that are called for redemption, as the case may be, prior to the maturity date. The Company may not redeem the Notes prior to November 20, 2024. The Notes are redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after November 20, 2024 and before the 41st scheduled trading day immediately preceding the maturity date, but only if the last reported sale price per share of the Common Stock has been at least 130% of the conversion price then in effect for a specified period of time. The Notes are the Company’s senior unsecured obligations and will rank senior in right of payment to any of the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Notes; rank equal in right of payment to any of the Company’s future unsecured indebtedness that is not so subordinated; be effectively subordinated in right of payment to any of the Company’s existing and future secured indebtedness to the extent of the value of the collateral securing such indebtedness; and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) of current or future subsidiaries of the Company. The Indenture also contains covenants, events of default and other provisions which are customary for offerings of convertible notes. We are in compliance with all covenants as of March 31, 2023. At March 31, 2023, the fair value of the Notes is $340,285. This is based on the quoted market price where the volume of activity is limited and not active and, thus, this is deemed a Level 2 fair value measurement.
The Company incurred $669 and $664 of debt issuance cost accretion for the three months ended March 31, 2023 and 2022, respectively. Debt issuance cost accretion of $2,014, $2,698, $2,714, and $2,395 is expected to be incurred in the remaining nine months of 2023 and in 2024, 2025 and 2026, respectively.
17

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(10) Redeemable Non-Controlling Interest
The following table shows changes in the RNCI related to Kumovis:

|  | Three Months Ended March 31,
(in thousands) |  | 2023 |
Balance at December 31, 2022 |  | $ | 1,760 |  |
Net loss |  | (108) |  |
Redemption value in excess of carrying value |  | (88) |  |
Translation adjustments |  | 198 |  |
Balance at March 31, 2023 |  | $ | 1,762 |  |

(11) Stock-Based Compensation
Stock Incentive Plans
The Company is authorized to grant shares of restricted stock, restricted stock units (“RSUs”), stock appreciation rights, cash incentive awards and options to purchase shares of Common Stock to employees and non-employee directors pursuant to its 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan also designates measures that may be used for performance awards and market-based awards. The vesting period for awards granted under the 2015 Plan is generally determined by the Board of Directors at the date of the grant. Generally, the awards vest one third each year, over 3 years.
Other Compensation Arrangements that Include Share Settlement
Regenerative Medicine Earnout Payments and Performance-Based Stock Units
On December 1, 2021, the Company acquired Volumetric Biotechnologies, Inc. (“Volumetric”). Pursuant to the terms of the related acquisition agreement, the Company may be required to pay milestone-based payments of up to $355,000 in the aggregate, all of which are incremental to the acquisition purchase price, upon (1) the achievement of seven discrete non-financial milestones that require attainment prior to either December 31, 2030 or December 31, 2035 and (2) the continued employment of certain key individuals from Volumetric. Each potential milestone-based payment is considered compensation expense, which the Company will recognize ratably from the point in time when a milestone is deemed probable of achievement through the estimated time of achievement. Each milestone payment will be settled approximately half in cash and half in shares of the Company’s Common Stock and, accordingly, the portion of the Company’s accrued liability (see Note 8) that is ultimately expected to be settled with the Company’s Common Stock is reflected in the disclosure of stock-based compensation included herein.
In addition, the Company has granted performance-based stock units (“PSUs”) with vesting terms that are based upon four individually-measured, non-financial milestones to other employees who work on advancements in regenerative medicine related to lungs and tissue organs. The PSUs associated with each individual milestone are recognized as compensation expense over the period commencing on the date that the respective milestone is deemed probable of being met through the anticipated date of achievement.
During the three months ended March 31, 2023 and 2022, the Company recognized compensation expense based upon the assumed achievement of (1) one Volumetric earnout payment milestone, for which the potential amount due to the sellers will be $65,000, and (2) one PSU milestone, for which the aggregate grant date fair value of the outstanding and unvested awards is $4,679. Ac hievement of each milestone is anticipated to occur as of the end of fiscal year 2025.
dp polar Earnout
On October 4, 2022, the Company acquired dp polar. Pursuant to the terms of the related acquisition agreement, the Company may be required to pay $2,229 incremental to the acquisition purchase price, which will be settled via the issuance of 250 shares of the Company’s Common Stock. The issuance and vesting of these shares is contingent on the continued employment of a certain key individual from dp polar through October 4, 2024. Upon assessment, management concluded that this potential obligation for the payment of an additional 250 in shares of Common Stock should be accounted for as compensation expense recognized over the required service period of the individual to whom the amount will potentially be paid and, accordingly, the related expense is reflected in the disclosure of stock-based compensation included herein.
18

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Stock-Based Compensation Activity and Expense
During the three months ended March 31, 2023, the Company granted 96 shares of restricted stock which had a weighted-average grant date fair value of $11.61 per share. The restricted stock awards generally vest ratably over three years.
The following table shows the stock-based compensation expense recognized during the three months ended March 31, 2023 and 2022:

|  | Three Months Ended
(in thousands) |  | March 31, 2023 |  | March 31, 2022 |  |
Stock-based compensation expense |  | $ | 10,292 |  |  | $ | 12,658 |  |  |
Tax benefit |  | $ | — |  |  | $ | — |  |  |

Included in stock-based compensation expense recognized for the three months ended March 31, 2023 and 2022 are $658 and $4,271, respectively, of accrued expense pertaining to annual incentive compensation for which settlement would ultimately occur using shares of the Company’s Common Stock. Also included in stock-based compensation expense for the three months ended March 31, 2023 and 2022 are $1,990 and $1,990, respectively, which relate to the portion of the Volumetric earnout expense recognized during each period that is expected to be settled using the Company’s Common Stock. Further, stock-based compensation expense for the three months ended March 31, 2023 and 2022 includes $274 and $0, respectively, of expense related to the dp polar earnout arrangement. Finally, stock-based compensation expense for the three months ended March 31, 2023 and 2022 includes $277 and $244, respectively, of expense related to the regenerative medicine PSUs.
As of March 31, 2023, there was $39,315 of unrecognized stock-based compensation expense related to all unvested share-based payment awards that the Company expects to recognize over a weighted-average period of 1.8 years.
(12) Interest and Other Income (Expense), Net

|  | Three Months Ended
(in thousands) |  | March 31, 2023 |  | March 31, 2022 |  |
Interest and other income (expense), net |  |  |  |  |  |
Foreign exchange (loss) gain, net |  | $ | (372) |  |  | $ | (2,218) |  |  |
Interest income (expense), net |  | 3,805 |  |  | 165 |  |  |
Other (expense) income, net |  | 442 |  |  | (230) |  |  |
Total interest and other income (expense), net |  | $ | 3,875 |  |  | $ | (2,283) |  |  |

Interest and other income (expense), net includes (1) interest income of $4,546 and $825 for the three months ended March 31, 2023 and 2022, respectively, and (2) interest expense of $741 and $660 for the three months ended March 31, 2023 and 2022, respectively.
(13) Income Taxes
We maintain the exception under ASC 740-270-30-36(b), “Accounting for Income Taxes,” for jurisdictions that do not have reliable estimates of ordinary income. Based on volatility in the industry, we have continued to use a year-to-date methodology in determining the effective tax rate for the quarter ended March 31, 2023.
For the quarter ended March 31, 2023, the Company’s effective tax rate was 0.0%. For the quarter ended March 31, 2022, the Company’s effective tax rate was (5.0)%. The differences between the U.S. statutory tax rate and the effective tax rates for the quarters ended March 31, 2023, and March 31, 2022, are primarily driven by a full valuation in various jurisdictions.
19

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(14) Net Earnings (Loss) Per Share
Basic net income (loss) per share is calculated by dividing net income (loss) attributable to 3D Systems’ Common Stock stockholders by the weighted average number of Common Stock shares outstanding during the applicable period. Diluted net income (loss) per share incorporates the additional shares issuable upon the assumed exercise of stock options, the vesting of restricted stock and RSUs, and the assumed conversion of debt, except in such case when (1) the inclusion of such shares or potential shares would be anti-dilutive or (2) when the vesting of restricted stock or RSUs is contingent upon one or more performance conditions that have not been met as of the balance sheet date.

| Three Months Ended
(in thousands, except per share amounts) | March 31, 2023 |  | March 31, 2022 |  |
Numerator for basic and diluted net (loss) income per share: |  |  |  |  |
Net (loss) income attributable to 3D Systems Corporation | $ | (29,421) |  |  | $ | (26,799) |  |  |
Redeemable non-controlling interest redemption value in excess of carrying value | (88) |  |  | — |  |  |
Net (loss) income attributable to common stock shareholders | $ | (29,509) |  |  | $ | (26,799) |  |  |
Denominator for net (loss) income per share: |  |  |  |  |
Weighted average shares – basic | 129,158 |  |  | 126,728 |  |  |
Dilutive effect of shares issuable under stock based compensation and other plans(1) | — |  |  | — |  |  |
Weighted average shares – diluted | 129,158 |  |  | 126,728 |  |  |
Net income (loss) per share – basic | $ | (0.23) |  |  | $ | (0.21) |  |  |
Net income (loss) per share – diluted | $ | (0.23) |  |  | $ | (0.21) |  |  |

(1) Equity awards are deemed anti-dilutive for the three months ended March 31, 2023 and 2022 because we reported a net loss for these periods.
The following table presents the potentially dilutive shares that have been excluded from the computation of diluted earnings (loss) per share attributable to Common Stock stockholders because their effect is considered anti-dilutive for the three months ended March 31, 2023 and 2022, respectively.

| Three Months Ended
(in thousands) | March 31, 2023 |  | March 31, 2022 |  |
Restricted stock and restricted stock units | 4,177 |  |  | 5,313 |  |  |
Stock options | 420 |  |  | 420 |  |  |
Total | 4,597 |  |  | 5,733 |  |  |

For the three months ended March 31, 2023, the table above excludes the following: (1) an estimate of 1,041 shares contingently issuable upon the achievement of certain milestones in the Volumetric earnout arrangement discussed in Note 11; (2) an estimate of 466 shares for the payment of accrued incentive compensation that is expected to be settled in shares; and (3) an estimate of 53 shares that are contingently issuable under the dp polar earnout arrangement discussed in Note 11. These share estimates are based on the aggregate liabilities recorded for the Volumetric earnout arrangement, fiscal year 2022 and fiscal year 2023 incentive compensation and the dp polar earnout arrangement at March 31, 2023, divided by the Company's year-to-date average share price of $10.19 per share.
For the three months ended March 31, 2022, the table above excludes the following: (1) an estimate of 152 shares contingently issuable to settle the March 31, 2022 liability accrued for the assumed achievement of certain milestones in the Volumetric earnout arrangement discussed in Note 11 and (2) and 245 shares attributable to the portion of the fiscal year 2022 bonus accrued as of March 31, 2022 to be settled in shares.
On November 16, 2021, the Company issued $460,000 in aggregate principal amount of 0% Convertible Senior Notes due November 15, 2026, as discussed in Note 9. The Notes’ impact to diluted shares will be calculated using the if-converted method as prescribed in ASU 2020-06. The Notes will increase the diluted share count when the average share price over a quarterly or annual reporting period is greater than $35.92 per share, the conversion price of the Notes. For the three months ended March 31, 2023 and 2022, the Notes were anti-dilutive on a stand-alone basis because the average share price during these periods did not exceed the conversion price, and because we had a net loss for each of the respective periods.
20

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(15) Accumulated Other Comprehensive Loss
The changes in the balances of accumulated other comprehensive loss by component are as follows:

| Three Months Ended March 31, 2023
(in thousands) | Foreign currency translation adjustment |  | Defined benefit pension plan |  | Unrealized loss on short-term investments |  | Total
Balance at December 31, 2022 | $ | (54,194) |  |  | $ | 700 |  |  | $ | (328) |  |  | $ | (53,822) |
Other comprehensive income (loss) | 3,413 |  | 12 |  |  | 108 |  | 3,533 |
Amounts reclassified from accumulated other comprehensive income (loss) a | — |  |  | (12) |  |  | 201 |  | 189 |
Balance at March 31, 2023 | $ | (50,781) |  |  | $ | 700 |  |  | $ | (19) |  |  | $ | (50,100) |
| Three Months Ended March 31, 2022
(in thousands) | Foreign currency translation adjustment |  | Defined benefit pension plan |  | Unrealized loss on short-term investments |  | Total
Balance at December 31, 2021 | $ | (35,464) |  |  | $ | (2,242) |  |  | $ | — |  |  | $ | (37,706) |
Other comprehensive income (loss) | (3,346) |  |  | 37 |  |  | (3,495) |  |  | (6,804) |
Amounts reclassified from accumulated other comprehensive income (loss) (a) | — |  |  | 64 |  |  | — |  |  | 64 |
Balance at March 31, 2022 | $ | (38,810) |  |  | $ | (2,141) |  |  | $ | (3,495) |  |  | $ | (44,446) |

(a) Amount reclassified into interest and other income (expense), net on the statement of operations. See Note 18 for detail regarding fair value measurements of unrealized gains (losses) on short-term investments.
The amounts presented in the table above are net of income taxes.
(16) Segment Information
T he Company’s operations are comprised of two reportable segments: Healthcare Solutions and Industrial Solutions. Effective January 1, 2023, the Company’s chief operating decision maker (“CODM”) placed an increased focus on Segment Adjusted EBTIDA when evaluating the performance of the Company’s reportable segments, among other measures, Segment Adjusted EBITDA. In addition, the methodology for allocating certain costs has been revised to more closely reflect changes in the Company's business and estimates of usage by the Company's segments. Prior year amounts have been reclassified to conform with current year presentation. The following table sets forth our operating results by segment for the three months ended March 31, 2023 and 2022:

| Revenue |  | Adjusted EBITDA
(in thousands) | March 31, 2023 |  | March 31, 2022 |  | March 31, 2023 |  | March 31, 2022
Healthcare Solutions | $ | 48,725 |  |  | $ | 64,345 |  |  | $ | 5,065 |  |  | $ | 15,769 |
Industrial Solutions | 72,511 |  |  | 68,656 |  |  | 6,902 |  |  | 6,565 |
Total Reportable segments | 121,236 |  |  | 133,001 |  |  | 11,967 |  |  | 22,334 |
Corporate and Other(1) | — |  |  | — |  |  | (22,061) |  |  | (20,411) |
Total Company | $ | 121,236 |  |  | $ | 133,001 |  |  | $ | (10,094) |  |  | $ | 1,923 |

21

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) Corporate is not an operating segment, but reflects expenses not directly attributable to and, accordingly, not allocated to our reportable segments. These expenses relate to corporate functions such as human resources, finance, and legal and include expenses such as salaries, benefits, and other related costs. Similar to the Company's operating segments, Corporate results are reported to and reviewed by the Company’s CODM on the basis of Adjusted EBITDA.
The following table provides a reconciliation of the Company’s reported net loss to the total of our reportable segment Adjusted EBITDA and corporate and other Adjusted EBITDA for the three months ended March 31, 2023 and 2022:

|  | Three Months Ended
(in thousands) |  | March 31, 2023 |  | March 31, 2022
Net loss attributable to 3D Systems Corporation |  | $ | (29,421) |  |  | $ | (26,799) |
Interest (income) expense, net |  | (3,805) |  |  | (165) |
Provision (benefit) for income taxes |  | 8 |  |  | 1,284 |
Depreciation expense |  | 5,312 |  |  | 5,818 |
Amortization expense |  | 3,239 |  |  | 2,678 |
Stock-based compensation expense |  | 10,292 |  |  | 12,658 |
Acquisition and divestiture-related expense |  | 2,677 |  |  | 3,682 |
Litigation costs |  | 79 |  |  | — |
Restructuring expense |  | 1,703 |  |  | 319 |
Redeemable non-controlling interest |  | (108) |  |  | — |
Other non-operating (income) expense |  | (70) |  |  | 2,448 |
Adjusted EBITDA |  | $ | (10,094) |  |  | $ | 1,923 |

(17) Commitments and Contingencies
Indemnification
In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant, and we are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.
To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors and officers insurance coverage that may enable us to recover future amounts paid, subject to a deductible and the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.
Litigation
Export Controls and Government Contracts Compliance Matter
In October 2017, we received an administrative subpoena from the Bureau of Industry and Security of the Department of Commerce (“BIS”) requesting the production of records in connection with possible violations of U.S. export control laws, including with regard to our former Quickparts.com, Inc. subsidiary. In addition, while collecting information responsive to the above-referenced subpoena, our internal investigation identified potential violations of the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State (“DDTC”) and potential violations of the Export Administration Regulations administered by the BIS. Thereafter, we submitted voluntary disclosures to BIS and DDTC identifying potentially unauthorized exports between 2012 and 2017, including to China, of controlled items including technical data. In connection with these matters, in August 2020, we received two federal grand jury subpoenas issued by the U.S. District Court for the Northern District of Texas. The Company responded to these two subpoenas and fully cooperated with the U.S. Department of Justice (“DOJ“) in the related investigation.
During 2022, we engaged in discussions with DDTC, BIS, and DOJ to settle the potential export control violations described
22

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
above. In February 2023, the Company settled these matters with all three agencies. As a part of these settlement agreements, the Company agreed to pay $15,048 in civil monetary penalties to these agencies, with an additional $10,000 in suspended penalty amounts to be allocated to remedial compliance measures required by DDTC. The penalty amounts were broken down as follows: DDTC $10,000 (in three installments over a three-year period), BIS $2,778, and DOJ $2,270. The first penalty installment payment to DDTC and the full penalty payments to BIS and to DOJ were made in the first quarter of 2023. To the extent any portion of the $10,000 suspended penalty is not expended on required remedial compliance measures by the end of the three-year term of the settlement agreement, then such shortfall shall be paid by the Company to DDTC. Accordingly, the $10,000 suspended penalty has not been recognized as a liability as of March 31, 2023 and will be recognized as incurred during the three-year term of the settlement agreement. The agencies are not criminally prosecuting the Company, nor anyone associated with the Company, and the Company is not subject to any administrative debarment. Over the course of our internal investigation, we made meaningful improvements to our compliance program and will continue to further enhance export compliance going forward.
Shareholder Suits
The Company and certain of its current and former executive officers have been named as defendants in a consolidated putative stockholder class action lawsuit pending in the United States District Court for the Eastern District of New York (the “District Court”). The action is styled In re 3D Systems Securities Litigation, No. 1:21-cv-01920-NGG-TAM (E.D.N.Y.) (the “Securities Class Action”). On July 14, 2021, the Court appointed a Lead Plaintiff for the putative class and approved his choice of Lead Counsel. Lead Plaintiff filed his Consolidated Amended Complaint (the “Amended Complaint”) on September 13, 2021, alleging that defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that the current and former executive officers named as defendants are control persons under Section 20(a) of the Exchange Act. The Amended Complaint was filed on behalf of stockholders who purchased shares of the Company’s Common Stock between May 6, 2020 and March 5, 2021, and seeks monetary damages on behalf of the purported class. Defendant moved to dismiss the Amended Complaint on February 15, 2022, and the motion was fully briefed in May 2022. On October 28, 2022, the parties notified the District Court that they reached an agreement in principle resolving this action, and on December 19, 2022, Lead Plaintiff filed a motion seeking entry of an order preliminarily approving the settlement and establishing notice procedures. The settlement is subject to both preliminary and final approval by the District Court. On April 15, 2022, the Company was informed the SEC is conducting a formal investigation of the Company related to, among other things, the allegations in the Securities Class Action, and the Company received subpoenas from the SEC for the production of documents and information related to its investigation as a follow on to a previous voluntary request for documents. The Company is cooperating with the SEC.
The Company has been named as a nominal defendant and certain of its current and former executive officers and directors have been named as defendants in derivative lawsuits pending in the United States District Court for the Eastern District of New York, the South Carolina Court of Common Pleas for the 16th Circuit, York County, and the Supreme Court of the State of New York, Kings County. The actions are styled Nguyen v. Joshi, et al., No. 21-cv-03389-NGG-TAM (E.D.N.Y.) (the “Nguyen Action”), Lesar v. Graves, et al., No. 2021CP4602308 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Lesar Action”), Scanlon v. Graves, et al., No. 2021CP4602312 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Scanlon Action”), Bohus v. Joshi, et al., No. 22-cv-2203-CBA-RML (E.D.N.Y.) (the “Bohus Action”), and Fernicola v. Clinton, et. al., No. 512613/2022 (N.Y., Kings County Supreme Court) (the “Fernicola Action”). The Complaints in the Nguyen and Bohus Actions, which were filed on June 15, 2021 and April 18, 2022, respectively, assert breach of fiduciary duty claims against all defendants and claims for contribution under the federal securities laws against certain of the defendants. The Complaints in the Lesar and Scanlon Actions, which were filed on July 26, 2021, assert breach of fiduciary duty and unjust enrichment claims against the defendants. The Complaint in the Fernicola Action was filed on May 2, 2022, and asserts claims for breach of fiduciary duty and waste of corporate assets against the director defendants. On August 27, 2021, the Nguyen Action was stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On October 26, 2021, the Lesar Action and the Scanlon Action were consolidated into a single stockholder derivative action, styled as In Re 3D Systems Corp. Shareholder Derivative Litigation, No. 2021CP4602308 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. Of York) (the “South Carolina Derivative Action”). On March 3, 2022, the South Carolina Derivative Action was stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On June 16, 2022, the Bohus Action was consolidated with the Nguyen Action (the “E.D.N.Y. Derivative Action”). The E.D.N.Y. Derivative Action is stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On August 15, 2022, the Fernicola Action was voluntarily dismissed without prejudice.
23

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The Company believes the claims alleged in the putative securities class action and derivative lawsuits are without merit and the Company intends to defend itself and its current and former officers vigorously.
Other
We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position.
In connection with the foregoing matters, we recognized a liability of $16,044 during the three months ended December 31, 2022, which includes the $10,000 DDTC civil monetary penalty being recognized at a discount using the risk-free interest rate. During the three months ended March 31, 2023, we paid $8,548 of this liability in accordance with the settlement agreements discussed above. Refer to Note 8 for details regarding our remaining short-term and long-term liabilities recorded for legal contingencies.
(18) Fair Value Measurements
Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy:
•Level 1 - Inputs are based on quoted prices in active markets for identical assets and liabilities.
•Level 2 - Inputs are based on observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
•Level 3 - One or more inputs are unobservable and significant.
Financial and nonfinancial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Cash equivalents and short-term investments are valued utilizing the market approach to measure fair value for financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of March 31, 2023 and December 31, 2022 because of the relatively short duration of these instruments.
24

3D SYSTEMS CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Assets measured at fair value on a recurring basis as of March 31, 2023 are summarized below:

| Fair Value Measurement as of March 31, 2023
| Fair Value Measurement |  | Balance Sheet Classification
(in thousands) | Fair Value Level |  | Cost Basis |  | Unrealized Gains (Losses) |  | Fair Value |  | Cash and Cash Equivalents |  | Short-term Investments and Marketable Securities |  |
Money market funds | Level 1 |  | $ | 451,508 |  |  | $ | — |  |  | $ | 451,508 |  |  | $ | 451,508 |  |  | $ | — |  |  |
Certificates of deposit | Level 2 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |
Commercial paper | Level 2 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |
Short-term bond mutual funds | Level 2 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |
Corporate bonds(a) | Level 2 |  | 4,046 |  |  | (19) |  |  | 4,027 |  |  | — |  |  | 4,027 |  |  |
Total |  |  | $ | 455,554 |  |  | $ | (19) |  |  | $ | 455,535 |  |  | $ | 451,508 |  |  | $ | 4,027 |  |  |

(a) Includes $745 and $742 of cost basis and fair market value, respectively, with a weighted average maturity of 1.0 years.
We did not have any transfers of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value measurement hierarchy during the three months ended March 31, 2023.
Assets measured at fair value on a recurring basis as of December 31, 2022 are summarized below:

| Fair Value Measurement as of December 31, 2022
| Fair Value Measurement |  | Balance Sheet Classification
(in thousands) | Fair Value Level |  | Cost Basis |  | Unrealized Gains (Losses) |  | Fair Value |  | Cash and Cash Equivalents |  | Short-term Investments and Marketable Securities |  |
Money market funds | Level 1 |  | $ | 232,018 |  |  | $ | — |  |  | $ | 232,018 |  |  | $ | 232,018 |  |  | $ | — |  |  |
Certificates of deposit | Level 2 |  | 990 |  |  | 6 |  |  | 996 |  |  | — |  |  | 996 |  |  |
Commercial paper | Level 2 |  | 1,281 |  |  | 6 |  |  | 1,287 |  |  | — |  |  | 1,287 |  |  |
Short-term bond mutual funds | Level 2 |  | 100,242 |  |  | (99) |  |  | 100,143 |  |  | — |  |  | 100,143 |  |  |
Corporate bonds(a) | Level 2 |  | 78,418 |  |  | (241) |  |  | 78,177 |  |  | — |  |  | 78,177 |  |  |
Total |  |  | $ | 412,949 |  |  | $ | (328) |  |  | $ | 412,621 |  |  | $ | 232,018 |  |  | $ | 180,603 |  |  |

(a) Includes $745 and $743 of cost basis and fair market value, respectively, with a weighted average maturity of 1.3 years.
(19) Subsequent Events
On May 1, 2023, the Company announced that it entered into an agreement to acquire Wematter AB (“Wematter”), a Swedish 3D printer manufacturer that will broaden 3D Systems’ Selective Laser Sintering (SLS) portfolio, for approximately $11,000 in cash, subject to customary post-closing adjustments. The Company may be required to pay an additional €2,000 in cash contingent on the achievement of certain post-closing performance conditions and the continued employment by the Company of certain Wematter key employees for two years after the closing date. If earned, the €2,000 is expected to be recognized as compensation expense over the 2-year service period. The acquisition is expected to close during July 2023.
On May 9, 2023, the Company announced a restructuring initiative to improve operating efficiencies throughout the organization and drive long-term value creation. This initiative is expected to reduce headcount by approximately 6%, with the majority of reductions being made in Corporate and business support functions which are predominantly located in the US and Europe. The Company expects to incur cash charges in the range of $3,500 - $4,500 for severance-related costs related to this initiative during 2023. The majority of these charges are expected to be incurred in the 2nd quarter of 2023, with the remainder occurring in the second half of 2023.
25

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read together with our unaudited condensed consolidated financial statements and notes thereto included in Item 1 of this Form 10-Q (the “Financial Statements”). Certain statements contained in this discussion may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that may affect our future performance that are discussed in greater detail under the heading “Forward Looking Statements” below and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”).
Business Overview
3D Systems Corporation (“3D Systems” or the “Company” or “we,” “our” or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and the Asia Pacific and Oceania region (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and digital design tools. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.
The Company has two reportable segments, Healthcare Solutions and Industrial Solutions. Healthcare S olutions includes dental, medical devices, personalized health services and regenerative medicine. Industrial S olutions includes aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable hundreds of thousands of production parts to be made through additive manufacturing each day.
Recent Developments
Acquisitions/Investments
The Company has made the following significant acquisitions and investments since the fourth quarter of 2021.
On October 4, 2022, we completed the acquisition of dp polar, a German-based designer and manufacturer of the industry’s first additive manufacturing system designed for true high-speed mass production of customized components, for $25.2 million, which includes $19.6 million paid in cash at closing, $7.1 million paid at closing via the issuance of the Company’s common stock, and a provisional $1.5 million estimated post-closing purchase price adjustment due to the Company from the sellers. An additional payment of $2.2 million via the issuance of 249,865 shares of the Company’s common stock is possible upon the continued employment of a certain key individual from dp polar through October 4, 2024. Central to dp polar’s patented continuous printing process is a large-scale, segmented, rotating print platform that eliminates the start/stop operations of virtually all additive manufacturing platforms. With dp polar’s technology and patented polar coordinate control, the print heads remain stationary above the rotating platform, providing a continuous print process. The acquisition’s near-term impact on the Company’s results of operations and cash flows has been dilutive.
On April 1, 2022, we completed the acquisition of 93.75% of Kumovis for an all-cash purchase price of $37.9 million. $3.6 million of the purchase price is deferred for up to fifteen months from the closing date and $0.1 million reflects the anticipated settlement of the related net working capital adjustment. Kumovis, which is part of the Healthcare Solutions segment, utilizes polyether ether keton or “PEEK” materials, which have properties that lend it to many medical applications, including many implant applications, that fit into our personalized healthcare s olutions operations. The acquisition’s near-term impact on the Company's results of operations and cash flows has been dilutive.
On April 1, 2022, we completed the acquisition of 100% of Titan for an all-cash purchase price of $39.0 million. Titan, which is part of the Industrial Solutions segment, is a pellet-based extrusion platform that addresses customer applications requiring large build volumes, superior performance, and improved productivity at significantly lower cost. We believe the acquisition of Titan will open up new markets in the Industrial Solutions segment. The acquisition’s near-term impact on the Company's results of operations and cash flows has been dilutive.
26

In March 2022, the Saudi Arabian Industrial Investments Company (“Dussur”) and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. 3D Systems is committed to an initial investment of approximately $6.5 million, of which $3.4 million was deposited in an escrow account during the three months ended December 31, 2022 and was reported as restricted cash within other assets on the balance sheet as of March 31, 2023 and December 31, 2022. In February 2023, the Company became a shareholder in the joint venture and now owns 49% of its common stock. Accordingly, the $3.4 million held in escrow plus an additional $3.1 million owed to the joint venture as of March 31, 2023 was deposited into a bank account of the joint venture during April 2023 for use in its operations. Additional future investments are contingent upon the achievement of certain milestones by the joint venture. The impact on the Company’s financial position, results of operations and cash flows is not expected to be material other than the cash outflow(s) related to the initial and contingent investments.
In March 2022, we made a $10.0 million investment for an approximate 26.6% ownership interest in Enhatch Inc. (“Enhatch”), the developer of the Intelligent Surgery Ecosystem. We simultaneously entered into a collaboration and supply agreement with Enhatch. We also obtained warrants to purchase additional shares of Enhatch and the right to purchase, in the future, the remaining shares of Enhatch that 3D Systems does not own if certain revenue targets are achieved. Enhatch's Intelligent Surgery Ecosystem provides technologies which streamline and scale the design and delivery of patient-specific medical devices by automating the process. Incorporating these capabilities into 3D Systems’ workflow for patient-specific solutions, which includes advanced software, expert treatment planning services, custom implants, instrumentation design, and industry-leading production processes, will help more efficiently meet the growing demand for personalized medical devices.
On December 1, 2021, we acquired Volumetric Biotechnologies, Inc. (“Volumetric”) for $40.2 million. Additional payments of up to $355.0 million are possible upon (1) the attainment of seven non-financial milestones, each of which requires achievement prior to either December 31, 2030 or December 31, 2035, and (2) the continued employment of certain key individuals from Volumetric. Volumetric’s mission is to develop the ability to manufacture human organs using bioprinting methods and the underlying technologies required to create these highly complex biological structures. With this acquisition, we expanded our capabilities and capacity in 3D printing related to bio-printing and regenerative medicine. Combining 3D Systems' regenerative medicine group with Volumetric’s highly complementary skill sets of biological expertise and cellular engineering is expected to accelerate our core regenerative medicine strategies which include the bio-printing of human organs, additional non-organ applications and bio-printing technologies for research labs. The acquisition’s near-term impact on the Company's results of operations and cash flows has been dilutive. Volumetric's operating results are reported in the Healthcare Solutions segment.
On November 1, 2021, we acquired Oqton for $187.8 million. Oqton is a software company that creates an intelligent, cloud-based MOS ("manufacturing operations system") platform tailored for flexible production environments that increasingly utilize a range of advanced manufacturing and automation technologies, including additive manufacturing solutions, in their production workflows. The cloud-based solution leverages the Industrial Internet of Things, artificial intelligence, and machine learning technologies to deliver a solution for customers to automate their digital manufacturing workflows, scale their operations and enhance their competitive position. The Oqton acquisition will allow the Company to expand its existing additive manufacturing software suite to the entire additive industry. Oqton's operating results are reported in the Industrial Solutions segment and the acquisition’s impact on the Company’s financial position, results of operations and cash flows has been dilutive.
Investing in Regenerative Medicine
As an early and continuing innovator in additive manufacturing, we have significant experience in bringing this technology to new markets. In 2022, we continued to expand our focus and investments in the application of additive manufacturing for regenerative medicine. Currently, our efforts in the area of regenerative medicine consist mainly of pre-commercial research and development (“R&D”) and involve three strategies.
27

The first strategy is the use of additive manufacturing for human organ transplantation. Each year, end-stage organ failure kills millions of people. However, the supply of donated organs is insufficient to meet the needs of patients seeking transplantation. During 2022, we made significant progress in our organ printing development program, which we are conducting together with a key strategic partner. This program was first established in 2017 and combines our legacy 3D printing expertise with our new capabilities in human tissue engineering from our acquisition of Volumetric in 2021, with the regenerative medicine and biotechnology expertise of our partner. To date, our program has focused on developing the capability to print scaffolds for human lungs, with a long-term goal of allowing all patients with end-stage lung disease to receive transplants which will enable them to enjoy long and active lives. Based upon the progress made toward this goal, the program has been expanded to include two additional human organs.
Our second strategy involves utilizing our bio-printing technology to manufacture non-organ human tissue scaffolds for use in transplantation and surgical reconstruction applications. We believe that continued progress in this area could result in significantly improved health outcomes for patients as well as open up attractive new growth markets and therapeutic applications for 3D printed, vascularized soft-tissue scaffolds. During 2022, we pursued this strategy as an internal development program that combines our legacy 3D printing capabilities with bio-printing and materials expertise that we have gained through our Volumetric acquisition, as well as through our work on the human lung program with our development partner.
Our third regenerative medicine strategy seeks to utilize our bio-printing capabilities to design and manufacture 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers. Currently, drug development is an expensive and time-consuming process, and many drug therapies that appear promising during pre-clinical trials fail during human clinical trials. We believe that “organs-on-chips” can accelerate the drug development process and reduce the cost of pre-clinical drug testing, as well as reduce the pharmaceutical industry’s reliance on animal testing. During 2022, we formed a new wholly-owned biotech company called Systemic Bio in order to accelerate our progress in this area. Systemic Bio combines 3D Systems’ legacy expertise in high-resolution 3D printing with advanced capabilities in bioprinting and biomaterials gained from our 2021 acquisition of Allevi, Inc. to design and market 3D-printed, vascularized “organs-on-chips” for sale to pharmaceutical industry customers. In the first quarter of 2023, we signed our first contract with a top pharmaceutical company with the aim of establishing a bioprinted vascularized tumor model to be used for drug discovery and development efforts in oncology. In addition to contract partnerships with third parties, we plan to continue providing internal funding to support Systemic Bio during the early stages of its growth, including for activities such as R&D facility expansion, product development and customer acquisition.
Background
We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services category includes maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.
Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.
In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this Management’s Discussion and Analysis, the price and mix effects relate to changes in revenue that are not able to be specifically related to changes in unit volume or foreign exchange.
How We Assess the Performance of Our Business
We manage operations through the two business segments described above. In addition to our consolidated GAAP financial measures, we review Adjusted EBITDA.
28

We believe Adjusted EBITDA is a helpful supplemental measure to assist us and investors in evaluating our operating results as they exclude certain items whose fluctuation from period to period do not necessarily correspond to changes in the operations of our business. Adjusted EBITDA represents net income (loss), plus income tax (provision) benefit, interest and other income (expense), net, stock-based compensation expense, amortization of intangible assets, depreciation expense, and certain other non-GAAP adjustments. We believe that the adjustments applied in presenting Adjusted EBITDA are appropriate to provide additional information to investors about our operating and financial performance without the effect of certain material non-cash items and about non-recurring items that we do not expect to continue at the same level in the future.
Management and our board of directors regularly use this measure in evaluating our operating and financial performance and in establishing discretionary annual compensation. Such measure is provided in addition to, and should not be considered to be a substitute for, or superior to, the comparable measure under GAAP. In addition, we believe that Adjusted EBITDA is frequently used by investors and other interested parties in the evaluation of issuers, many of which also present Adjusted EBITDA when reporting their results in an effort to facilitate an understanding of their operating and financial results.
Adjusted EBITDA should not be considered as an alternative to net income (loss) or any other performance measure derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and you should not consider such measure either in isolation or as a substitute for analyzing our results as reported under GAAP.
For further information regarding Adjusted EBITDA, see “Reconciliation of non-GAAP Measures” below.
Consolidated Financial Results for the Three Months Ended March 31, 2023 and 2022

| Three Months Ended |
(in thousands) | March 31, 2023 |  | March 31, 2022 |
Revenue: |  |  |  |
Products | $ | 84,388 |  |  | $ | 100,551 |  |
Services | 36,848 |  |  | 32,450 |  |
Total revenue | 121,236 |  |  | 133,001 |  |
Cost of sales: |  |  |  |
Products | 49,880 |  |  | 58,472 |  |
Services | 24,258 |  |  | 20,734 |  |
Total cost of sales | 74,138 |  |  | 79,206 |  |
Gross profit | 47,098 |  |  | 53,795 |  |
Operating expenses: |  |  |  |
Selling, general and administrative | 58,285 |  |  | 55,415 |  |
Research and development | 22,209 |  |  | 21,612 |  |
Total operating expenses | 80,494 |  |  | 77,027 |  |
Loss from operations | (33,396) |  |  | (23,232) |  |
Interest and other income (expense), net | 3,875 |  |  | (2,283) |  |
(Loss) income before income taxes | (29,521) |  |  | (25,515) |  |
(Provision) benefit for income taxes | (8) |  |  | (1,284) |  |
Net (loss) income before redeemable non-controlling interest | (29,529) |  |  | (26,799) |  |
Less: net (loss) attributable to redeemable non-controlling interest | (108) |  |  | — |  |
Net (loss) income attributable to 3D Systems Corporation | $ | (29,421) |  |  | $ | (26,799) |  |
Other Financial Data: |  |  |  |
Adjusted EBITDA | $ | (10,094) |  |  | $ | 1,923 |  |

Consolidated revenue
The following table sets forth changes in our products and services revenue for the three months ended March 31, 2023 and 2022.
29

(Dollars in thousands) | Products |  | Services |  | Total
Revenue — 2022 | $ | 100,551 |  |  | 75.6 | % |  | $ | 32,450 |  |  | 24.4 | % |  | $ | 133,001 |  |  | 100.0 | %
Change in revenue: |  |  |  |  |  |  |  |  |  |  |
Volume | (14,279) |  |  | (14.2) | % |  | 5,231 |  |  | 16.1 | % |  | (9,048) |  |  | (6.8) | %
Price/mix | 343 |  |  | 0.3 | % |  | — |  |  | — | % |  | 343 |  |  | 0.3 | %
Foreign currency translation | (2,227) |  |  | (2.2) | % |  | (833) |  |  | (2.6) | % |  | (3,060) |  |  | (2.3) | %
Net change | (16,163) |  |  | (16.1) | % |  | 4,398 |  |  | 13.5 | % |  | (11,765) |  |  | (8.8) | %
Revenue — 2023 | $ | 84,388 |  |  | 69.6 | % |  | $ | 36,848 |  |  | 30.4 | % |  | $ | 121,236 |  |  | 100.0 | %

Products revenue
For the three months ended March 31, 2023, products revenue decreased by $16.2 million, or 16.1%, as compared to the three months ended March 31, 2022. The decrease in products revenue was primarily driven by a reduction in sales volumes of $14.3 million, or 14.2%, due to a $19.1 million decrease in volume within our Healthcare Solutions segment, partially offset by a $4.8 million increase in volume within our Industrial Solutions segment. The lower volume within our Healthcare Solutions segment was primarily due to lower sales to the dental orthodontics market, as the demand for related elective dental procedures that our products support has been impacted by current economic conditions.
Services revenue
For the three months ended March 31, 2023, services revenue increased by $4.4 million, or 13.5%, as compared to the three months ended March 31, 2022. The increase in services revenue was primarily due to an increase in sales volume of $3.4 million and $1.8 million in our Healthcare Solutions and Industrial Solutions segments, respectively. The increase in the services sales volume realized by our Healthcare Solutions segment primarily was driven by higher revenue generated from both virtual surgical planning services and advanced manufacturing services related to medical devices. The increase in the services sales volume of our Industrial Solutions segment was attributable to maintenance contracts and other repair services, as well as installation and training services.
Total revenue
For the three months ended March 31, 2023, revenue decreased by $11.8 million, or 8.8%, as compared to the three months ended March 31, 2022 as the decrease in our products revenue exceeded the increase in our services revenue, as described above.
Consolidated gross profit

| Three Months Ended |  |  |  |  |  |  |  |
| March 31, 2023 |  | March 31, 2022 |  | Change in Gross Profit |  | Change in Gross Profit Margin
(Dollars in thousands) | Gross Profit |  | Gross Profit Margin |  | Gross Profit |  | Gross Profit Margin |  | $ |  | % |  | Percentage Points |  | %
Products | $ | 34,508 |  |  | 40.9 | % |  | $ | 42,079 |  |  | 41.8 | % |  | $ | (7,571) |  |  | (18.0) | % |  | (0.9) |  |  | (2.2) | %
Services | 12,590 |  |  | 34.2 | % |  | 11,716 |  |  | 36.1 | % |  | 874 |  |  | 7.5 | % |  | (1.9) |  |  | (5.3) | %
Total | $ | 47,098 |  |  | 38.8 | % |  | $ | 53,795 |  |  | 40.4 | % |  | $ | (6,697) |  |  | (12.4) | % |  | (1.6) |  |  | (4.0) | %

Products gross profit and gross profit margin
30

For the three months ended March 31, 2023, gross profit from products sales decreased by $7.6 million, or 18.0%, as compared to the three months ended March 31, 2022. The decrease in gross profit from products sales is primarily due to the 16.1% decrease in products sales revenue, as well as input cost inflation and unfavorable changes in product mix.
Services gross profit and gross profit margin
For the three months ended March 31, 2023, gross profit from services sales increased $0.9 million, or 7.5%, as compared to the three months ended March 31, 2022. The increase in gross profit from services sales is driven by the 13.5% increase in services revenue, partially offset by input cost inflation and unfavorable changes in product mix.
Consolidated selling, general and administrative expense
Selling, general and administrative ("SG&A") expense for the three months ended March 31, 2023 increased $2.9 million, or 5.2%, to $58.3 million as compared to $55.4 million for the three months ended March 31, 2022. SG&A expense increased $2.0 million due to the Company’s acquisitions of Titan, Kumovis, and dp polar during fiscal year 2022, as each of these acquisitions was consummated subsequent to March 31, 2022 and, accordingly, were not part of the Company's results for the period then ended. In addition to the impact of the Company's acquisitions, the increase in SG&A costs was driven by higher professional services fees for the three months ended March 31, 2023 due to the increased usage of consultants and third-party contractors, as well as increased fees incurred in connection with audit and tax services.
Consolidated research and development expense
Research and development ("R&D") expense for the three months ended March 31, 2023 increased $0.6 million, or 2.8%, to $22.2 million as compared to $21.6 million for the three months ended March 31, 2022. The increase was primarily due to a $1.3 million increase in expenses related to the Company’s acquisitions of Titan, Kumovis, and dp polar during fiscal year 2022, as each of these acquisitions was consummated subsequent to March 31, 2022 and, accordingly, were not part of the Company's results for the period then ended.
Consolidated operating loss
Our operating loss for the three months ended March 31, 2023 was $33.4 million, compared to a $23.2 million operating loss for the three months ended March 31, 2022, due to lower gross profit and higher SG&A and R&D expenses as discussed above.
Interest and other income (expense), net
The following table sets forth the components of interest and other income (expense), net for the three months ended March 31, 2023 and 2022.

|  | Three Months Ended
(in thousands) |  | March 31, 2023 |  | March 31, 2022 |  |
Interest and other income (expense), net |  |  |  |  |  |
Foreign exchange loss |  | $ | (372) |  |  | $ | (2,218) |  |  |
Interest income (expense), net |  | 3,805 |  |  | 165 |  |  |
Other income (expense), net |  | 442 |  |  | (230) |  |  |
Total interest and other (expense) income, net |  | $ | 3,875 |  |  | $ | (2,283) |  |  |

For the three months ended March 31, 2023, interest income (expense), net increased as compared to the same period last year due to higher interest income earned on cash and cash equivalents resulting from increased interest rates.
Net (loss) income
31

The following table sets forth the net (loss) income for the three months ended March 31, 2023, and 2022.

| Three Months Ended |  |
(in thousands, except per share amounts) | March 31, 2023 |  | March 31, 2022 |  |
(Loss) income before income taxes | $ | (29,521) |  |  | $ | (25,515) |  |  |
(Provision) benefit for income taxes | (8) |  |  | (1,284) |  |  |
Net (loss) income before redeemable non-controlling interest | (29,529) |  |  | (26,799) |  |  |
Less: net (loss) attributable to redeemable non-controlling interest | (108) |  |  | — |  |  |
Net (loss) income attributable to 3D Systems Corporation | $ | (29,421) |  |  | $ | (26,799) |  |  |
Net (loss) income per common share: |  |  |  |  |
Basic | $ | (0.23) |  |  | $ | (0.21) |  |  |
Diluted | $ | (0.23) |  |  | $ | (0.21) |  |  |

Our tax provision for the three months ended March 31, 2023 was de minimis, as compared to a $1.3 million tax provision for the three months ended March 31, 2022. The Company's effective tax rates for the three months ended March 31, 2023 and 2022 were significantly below the U.S. and foreign jurisdictions' statutory rates due to the Company's reported losses and the maintenance of a valuation allowance against deferred tax assets generated by such losses due to the Company's conclusion that it is more likely than not that its deferred tax assets will not be realized in various tax jurisdictions.
The net loss attributable to redeemable non-controlling interest reflects the portion of the loss incurred by Kumovis that is attributable to non-controlling interest holders. A similar amount was not reported for the three months ended March 31, 2022, as Kumovis was not acquired until April 1, 2022.
The increase in the net loss attributable to 3D Systems for the three months ended March 31, 2023, as compared to the net loss attributable to 3D Systems for the three months ended March 31, 2022, was primarily driven by an increase in the Company's loss from operations for the period, partially offset by lower foreign exchange transaction losses and higher interest and other income for the period.
Adjusted EBITDA (Non-GAAP)
The decrease in the Company's Adjusted EBITDA from $1.9 million for the three months ended March 31, 2022 to negative $10.1 million for the three months ended March 31, 2023 was primarily driven by the $10.2 million increase in the Company's reported operating loss (as described above). As shown in the reconciliation or our reported Net Loss to Adjusted EBITDA (below), the remaining change of $1.8 million in our Adjusted EBITDA reported for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, was primarily driven by changes in the amounts added back for stock compensation expense, acquisition and divestiture-related expense, and restructuring expense, each of which is included in our reported operating loss.
Reconciliation of Non-GAAP Measures
The table that follows provides a reconciliation of the Company's reported Net Loss to Adjusted EBITDA. Refer to the discussion of "How We Assess the Performance of Our Business" for additional information regarding Adjusted EBITDA and why management believes this measure provides useful information regarding the Company's results of operations.
32

|  | Three Months Ended
(in thousands) |  | March 31, 2023 |  | March 31, 2022
Net Loss |  | $ | (29,421) |  |  | $ | (26,799) |
Interest (income) expense, net |  | (3,805) |  |  | (165) |
Provision (benefit) for income taxes |  | 8 |  |  | 1,284 |
Depreciation expense |  | 5,312 |  |  | 5,818 |
Amortization expense |  | 3,239 |  |  | 2,678 |
Stock-based compensation expense |  | 10,292 |  |  | 12,658 |
Acquisition and divestiture-related expense |  | 2,677 |  |  | 3,682 |
Litigation costs |  | 79 |  |  | — |
Restructuring expense |  | 1,703 |  |  | 319 |
Redeemable non controlling interest |  | (108) |  |  | — |
Other non-operating (income) expense, net |  | (70) |  |  | 2,448 |
Adjusted EBITDA |  | $ | (10,094) |  |  | $ | 1,923 |

33

Segment Financial Results for the Three Months Ended March 31, 2023 and 2022
Effective January 1, 2023, the Chief Operating Decision Maker (“CODM”) evaluates the performance of the Company’s reportable segments based on, among other measures, Segment Adjusted EBITDA. In addition, the methodology for allocating certain costs has been revised to more closely reflect changes in the Company's business and estimates of usage by the Company's segments. Prior year amounts have been reclassified to conform with current year presentation. The following table presents the revenue and Adjusted EBITDA amounts reported by each of our segments and non-allocated corporate amounts for the three months ended March 31, 2023 and 2022:

| Revenue |  | Adjusted EBITDA
(in thousands) | March 31, 2023 |  | March 31, 2022 |  | Change |  | March 31, 2023 |  | March 31, 2022 |  | Change
Healthcare Solutions | $ | 48,725 |  |  | $ | 64,345 |  |  | $ | (15,620) |  |  | $ | 5,065 |  |  | $ | 15,769 |  |  | $ | (10,704) |
Industrial Solutions | 72,511 |  |  | 68,656 |  |  | 3,855 |  |  | 6,902 |  |  | 6,565 |  |  | 337 |
Corporate and Other | — |  |  | — |  |  | — |  |  | (22,061) |  |  | (20,411) |  |  | (1,650) |
Total Company | $ | 121,236 |  |  | $ | 133,001 |  |  | $ | (11,765) |  |  | $ | (10,094) |  |  | $ | 1,923 |  |  | $ | (12,017) |

Healthcare Solutions
Revenue
For the three months ended March 31, 2023, Healthcare Solutions revenue decreased $15.6 million, or 24.3%, as compared to the three months ended March 31, 2022. The decrease in segment revenue was primarily due to a 46.2% reduction in sales to our dental orthodontic market as the demand for related elective dental procedures that our products support has been impacted by current economic conditions. The reduction in dental orthodontic market sales was partially offset by growth of 21.0% in other non-dental sales as compared to the three months ended March 31, 2022.
Adjusted EBITDA
For the three months ended March 31, 2023, Adjusted EBITDA for our Healthcare Solutions segment decreased $10.7 million, or 67.9%, as compared to the three months ended March 31, 2022, which was primarily driven by the decrease in segment revenue as well as a $2.5 million increase in operating expenses. The increase in operating expenses was primarily related to investments in our regenerative medicine efforts for bioprinting technologies as well as expenses from recently acquired businesses.
Industrial Solutions
Revenue
For the three months ended March 31, 2023, Industrial Solutions revenue increased $3.9 million, or 5.6%, as compared to the three months ended March 31, 2022. The increase in segment revenue was primarily due to a 9.8% increase in sales volumes partially offset by the negative impacts of foreign exchange. Excluding the impacts of foreign exchange, revenue for our Industrial Solutions segment increased by 9.3%.
Adjusted EBITDA
For the three months ended March 31, 2023, Adjusted EBITDA for our Industrial Solutions segment increased $0.3 million, or 5.1%, as compared to the three months ended March 31, 2022, which was primarily driven by higher overall sales volumes, partially offset by a decrease in segment gross profit margin driven by cost inflation and a $0.8 million increase in operating expenses. The increase in operating expenses was primarily driven by recent acquisitions.
Corporate and Other
Adjusted EBITDA
For the three months ended March 31, 2023, Corporate and Other Adjusted EBITDA was negative $22.1 million, as compared to negative $20.4 million for the three months ended March 31, 2022. The decrease of $1.7 million was primarily driven by an increase in corporate finance and corporate administrative costs attributable to professional services due to an increased usage
34

of consultants and third-party contractors, as well as increased fees incurred in connection with audit and tax services.
Liquidity and Capital Resources
The following table sets forth the Company's operating working capital at March 31, 2023 and December 31, 2022.

|  |  | Change
(Dollars in thousands) | March 31, 2023 |  | December 31, 2022 |  | $ |  | %
Cash and cash equivalents | $ | 525,898 |  |  | $ | 388,134 |  |  | $ | 137,764 |  |  | 35.5 | %
Short-term investments | 4,027 |  |  | 180,603 |  |  | (176,576) |  |  | (97.8) | %
Accounts receivable, net | 94,677 |  |  | 93,886 |  |  | 791 |  |  | 0.8 | %
Inventories | 147,365 |  |  | 137,832 |  |  | 9,533 |  |  | 6.9 | %
| 771,967 |  |  | 800,455 |  |  | (28,488) |  |  | (3.6) | %
Less: |  |  |  |  |  |  |
Current lease liabilities | 10,542 |  |  | 9,036 |  |  | 1,506 |  |  | 16.7 | %
Accounts payable | 51,415 |  |  | 53,826 |  |  | (2,411) |  |  | (4.5) | %
Accrued and other liabilities | 54,159 |  |  | 55,571 |  |  | (1,412) |  |  | (2.5) | %
| 116,116 |  |  | 118,433 |  |  | (2,317) |  |  | (2.0) |
Operating working capital | $ | 655,851 |  |  | $ | 682,022 |  |  | $ | (26,171) |  |  | (3.8) | %

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures.
At March 31, 2023, cash and cash equivalents and short-term investments totaled $529.9 million and decreased $38.8 million since December 31, 2022. This decrease resulted primarily from cash used in operations of $27.7 million (which includes $8.5 million of cash paid for legal settlements, see Note 17), capital expenditures of $9.0 million, and taxes paid related to net-share settlement of equity awards of $2.1 million.
Cash held outside the U.S. at March 31, 2023 was $60.0 million, or 11.4%, of total cash and cash equivalents, compared to $58.4 million, or 15.0%, of total cash and cash equivalents at December 31, 2022. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. would not incur significant federal and state taxes. However, these dividends are subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limit exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.
The changes that make up the other components of working capital not discussed above resulted from the ordinary course of business. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments.
35

Cash Flow
The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash on hand cash, cash equivalents and short-term investments, cash flow from operations, which can vary widely from quarter to quarter, and financing activities as necessary. We expect that cash flow from operations, cash, cash equivalents and short-term investments, and other sources of liquidity, such as issuing equity or debt securities, subject to market conditions, will be available and sufficient to meet all foreseeable cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:

|  | Three Months Ended |  |
(in thousands) |  | March 31, 2023 |  | March 31, 2022 |  | Dollar Change
Cash flow used in operating activities |  | $ | (27,722) |  |  | $ | (15,125) |  |  | $ | (12,597) |
Cash flow used in investing activities |  | 167,829 |  |  | (373,209) |  |  | 541,038 |
Cash flow used in financing activities |  | (2,294) |  |  | (12,518) |  |  | 10,224 |

Cash flow from operations
For the three months ended March 31, 2023, cash used in operating activities was $27.7 million and cash used in operating activities for the three months ended March 31, 2022 was $15.1 million. The $12.6 million increase in cash flow used in operating activities during the three months ended March 31, 2023, as compared to the same period of the prior year, is primarily due to $8.5 million of cash paid for legal settlements in the three months ended March 31, 2023 (see Note 17) in addition to a seasonal increase in inventory balances.
Cash flow from investing activities
For the three months ended March 31, 2023, cash provided by investing activities was $167.8 million, which included $176.9 million of proceeds from the sales and maturities of short-term investments, partially offset by capital expenditures of $9.0 million.
For the three months ended March 31, 2022, cash used in investing activities was $373.2 million, which included $366.0 million of purchases of short-term investments, cash used for acquisitions and other investments of $9.3 million and capital expenditures of $4.1 million, partially offset by $6.2 million of proceeds from the sales and maturities of short-term investments.
Cash flow from financing activities
For the three months ended March 31, 2023, the cash flow used in financing activities was $2.3 million primarily due to taxes paid related to the net-share settlement of equity awards of $2.1 million.
For the three months ended March 31, 2022, the cash flow used in financing activities was $12.5 million primarily due to taxes paid related to the net-share settlement of equity awards of $10.1 million and the $2.3 million payment for the acquisition of a non-controlling interest.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements and do not utilize any “structured debt,” “special purpose” or similar unconsolidated entities for liquidity or financing purposes.
Material Cash Requirements
The Company's material cash requirements consist of the following contractual and other obligations:
Indebtedness
At March 31, 2023, we had $460 million of outstanding 0% convertible notes which mature in November of 2026. Management may consider pursuing additional long-term financing when it is appropriate in light of cash requirements for operations or other strategic opportunities, which could result in higher financing costs.
36

Purchase Commitments
We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery.
Leases
The Company had operating and financing lease obligations (inclusive of interest) of $89.5 million at March 31, 2023, primarily related to real estate and equipment leases, of which approximately $11.0 million in payments are expected over the remainder of 2023. Additionally, at March 31, 2023, the Company had $14.2 million in lease obligations for which the leases have not commenced as the facilities are under construction by the landlord.
Dussur
In March 2022, Dussur and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. 3D Systems is committed to an initial investment of approximately $6.5 million, of which $3.4 million was deposited in an escrow account during the three months ended December 31, 2022 and was reported as restricted cash within other assets on the balance sheet as of March 31, 2023 and December 31, 2022. In February 2023, the Company became a shareholder in the joint venture and now owns 49% of its common stock. Accordingly, the $3.4 million held in escrow plus an additional $3.1 million owed to the joint venture as of March 31, 2023 was deposited into a bank account of the joint venture during April 2023 for use in its operations. Additional future investments are contingent upon the achievement of certain milestones by the joint venture. The impact on the Company’s financial position, results of operations and cash flows is not expected to be material other than the cash outflow(s) related to the initial and contingent investments.
Sources of Funding to Satisfy Material Cash Requirements
The Company believes that it has the financial resources needed to meet its cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend, among other things, on the Company’s profitability and its ability to manage working capital requirements. The Company may also borrow from various sources as described above.
Other Contractual Commitments
Convertible Notes
We were in compliance with all covenants of the outstanding 0% convertible notes due November 2026 as of March 31, 2023.
Indemnification
In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.
To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits.
37

Critical Accounting Estimates
Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
As of the date of this report, there have been no changes to our critical accounting estimates described in the 2022 Form 10-K that have had a material impact on our condensed consolidated financial statements and related notes.
Forward-Looking Statements
Certain statements made in this Form 10-Q that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include without limitation:
•impact on our business as a result of macroeconomic events, including the Russia-Ukraine war and other geopolitical risks, recession, supply chain disruptions and foreign exchange volatility;
•our ability to deliver products that meet changing technology and customer needs;
•our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
•impact of future write-off or write-downs of goodwill and intangible assets;
•the concentration of revenue and credit risk exposure from our largest customer;
•our ability to acquire and enforce intellectual property rights and defend such rights against third party claims;
•our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
•failure of our information technology infrastructure or inability to protect against cyber-attack;
•our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;
•our ability to generate net cash flow from operations;
•our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
•our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
•fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
•our ability to efficiently conduct business outside the U.S.;
•our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
•our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
•product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
•our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
•our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
•disruption in our management information systems for inventory management, distribution, and other key functions;
•compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
38

•our ability to maintain our status as a responsible contractor under federal rules and regulations;
•changes in, or interpretation of, tax rules and regulations; and
•the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2022 Form 10-K.
Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
For a discussion of market risks at December 31, 2022, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2022 Form 10-K. During the three months ended March 31, 2023, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2022.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of March 31, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. These controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, in a manner to allow timely decisions regarding required disclosures. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of March 31, 2023 due to the following two material weaknesses in internal control over financial reporting:
•We did not design or maintain effective controls in response to the risks of material misstatement, including designing and maintaining formal accounting policies, procedures, and controls over significant accounts and disclosures to achieve complete, accurate and timely financial accounting, reporting and disclosures, with respect to: (1) revenue, receivables and deferred revenue, including the input of executed contract terms into the Company’s information systems that perform revenue recognition; and (2) the review of internally prepared reports and analyses utilized in the financial closing process.
Notwithstanding the existence of the material weaknesses described above, management believes that the condensed consolidated financial statements included in this Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows as of and for the periods presented, in conformity with GAAP.
Management’s Plan for Remediation
The material weaknesses described above were initially identified at December 31, 2020 and continued to exist at December 31, 2022. However, as a result of the remediation plan we commenced in January 2021, the number of control deficiencies that aggregated into the material weaknesses at December 31, 2022 were significantly reduced as compared to December 31, 2020. The remediation plan we began in January 2021 is designed to improve our internal control over financial reporting and remediate the related control deficiencies that led to these material weaknesses. In response to these deficiencies, management, with the oversight of the Audit Committee of the Board of Directors, has identified and implemented steps to remediate the material weaknesses.
During the year ended December 31, 2022, the Company completed the implementation of the following remedial measures designed to address the material weaknesses and to continue to improve our internal control over financial reporting.
•Established a formal controls governance committee in the first quarter of 2022 to manage and enhance the oversight and execution of internal controls. The controls governance committee consists of members of senior leadership, which meets monthly or more frequently as needed.
39

•Retained an outside firm with expertise in the design and execution of internal controls over financial reporting to examine our control design, perform a root cause analysis as to why certain controls have not been and continue to not be properly executed, and to advise on changes in the design of our controls and procedures and implementation of our remediation activities.
•Enhanced the global control environment, including testing in 2022 of a significant number of additional business process and information technology controls.
•Implemented software to manage and administer account reconciliations.
•Revamped and expanded our internal disclosure processes to provide greater representation across functions and improve opportunities to identify matters requiring accounting disposition or disclosures.
•Implemented software enhancements, including a tax reporting solution for our tax provision process.
•Redesigned controls related to the accounting for the income tax process.
•Engaged a third party to review our quarterly and annual tax calculations.
•Hired additional experienced resources with backgrounds in income tax accounting.
Our remaining internal control remediation efforts are expected to include the following:
•Design and implementation of enhanced policies, procedures and controls relating to our revenue recognition and our closing and financial reporting process.
•Redesign of existing management review controls, including the input of executed contract terms into the Company’s information systems that perform revenue recognition.
•Hire and retain additional staff with sufficient experience and knowledge in GAAP financial reporting matters and internal control over financial reporting.
•Train appropriate personnel in the effective design and execution of our enhanced policies, procedures and controls, including the importance of the ongoing, consistent effective execution of such procedures and controls.
•Initiation of a robust finance transformation initiative with dedicated resources tasked to create a more efficient close process and implement key technologies to enable a more mature and automated control environment.
We are committed to the remediation of all material weaknesses and expect to successfully implement enhanced control processes. However, as we continue to evaluate, and work to improve our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary. Therefore, we cannot assure you when we will remediate such weaknesses, nor can we be certain that additional actions will not be required or the costs of any such additional actions. Moreover, we cannot assure you that additional material weaknesses will not arise in the future.
Changes in Internal Control Over Financial Reporting
We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses described above. Except as noted above, there were no changes in the Company’s internal control over financial reporting during the three months ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
The information relating to legal proceedings set forth under the header “Litigation” in Note 17 to the Financial Statements in Part I, Item 1 of this Form 10-Q is incorporated herein by reference.
Item 1A. Risk Factors
There are no material changes to the risk factors previously disclosed in our 2022 Form 10-K in response to Item 1A, “Risk Factors” in the 2022 Form 10-K.
40

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuance of Unregistered Securities and Issuer Purchases of Equity Securities
Issuances of Unregistered Securities
None.
Issuer purchases of equity securities
We did not repurchase any of our equity securities in the open market during the three months ended March 31, 2023; however, shares of common stock were surrendered to us for payment of tax withholding obligations in connection with the vesting of restricted stock awards and units pursuant to our Amended and Restated 2015 Incentive Stock Plan.

| Total number of shares (or units) purchased |  | Average price paid per share (or unit) |
January 1, 2023 - January 31, 2023 | 41,697 |  |  | $ | 9.00 |  |
February 1, 2023 - February 28, 2023 | 45,751 |  |  | 11.66 |  |
March 1, 2023 - March 31, 2023 | 120,097 |  |  | 10.29 |  |
Total | 207,545 |  | a | $ | 10.33 |  | b

a.Represents shares of common stock surrendered to us for payment of tax withholding obligations in connection with the vesting of restricted stock awards and units.
b.The average price paid reflects the average market value of shares withheld for tax purposes.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Not applicable.
Item 6. Exhibits
41

(a)(3) | Exhibits |
| The following exhibits are included as part of this filing and incorporated herein by this reference: |
3.1 | Certificate of Incorporation of Registrant. (Incorporated by reference to Exhibit 3.1 to Registrant’s Form 8-B filed on August 16, 1993, and the amendment thereto, filed on Form 8-B/A on February 4, 1994.) |
3.2 | Amendment to Certificate of Incorporation filed on May 23, 1995. (Incorporated by reference to Exhibit 3.2 to Registrant’s Registration Statement on Form S-2/A, filed on May 25, 1995.) |
3.3 | Certificate of Amendment of Certificate of Incorporation filed with Secretary of State of Delaware on May 19, 2004. (Incorporated by reference to Exhibit 3.1 to Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004, filed on August 5, 2004.) |
3.4 | Certificate of Amendment of Certificate of Incorporation filed with Secretary of State of Delaware on May 17, 2005. (Incorporated by reference to Exhibit 3.1 to Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2005, filed on August 1, 2005.) |
3.5 | Certificate of Amendment of Certificate of Incorporation filed with the Secretary of State of Delaware on October 7, 2011. (Incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K, filed on October 7, 2011.) |
3.6 | Certificate of Amendment of Certificate of Incorporation filed with the Secretary of State of Delaware on May 21, 2013. (Incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K, filed on May 22, 2013.) |
3.7 | Amended and Restated By-Laws. (Incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K, filed on March 15, 2018.) |
4.1 | Specimen Common Stock Certificate. (Incorporated by reference to Exhibit 4.1 to Registrant’s Registration Statement on Form S-3 (Registration No. 333-182065), filed on June 12, 2012.) |
4.2 | Description of Common Stock. (Incorporated by reference to Exhibit 4.2 to Registrant's Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 26, 2020.) |
4.3 | Indenture, dated as of November 16, 2021, between 3D Systems Corporation and The Bank of New York Mellon Trust Company, N.A., as trustee. (Incorporated by reference to the Exhibit 4.1 of the Registrant’s Current Report on Form 8-K filed on November 17, 2021.) |
4.4 | Form of 0% Convertible Notes due 2026 (included in Exhibit 4.3). (Incorporated by reference to the Exhibit 4.2 of the Registrant’s Current Report on Form 8-K filed on November 17, 2021.) |
31.1† | Certification of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 10, 2023. |
31.2† | Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 10, 2023. |
32.1† | Certification of Principal Executive Officer filed pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 10, 2023. |
32.2† | Certification of Principal Financial Officer filed pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 10, 2023. |
101.INS† | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because the its XBRL tags are embedded within the Inline XBRL document.In |
101.SCH† | Inline XBRL Taxonomy Extension Scheme Document |
101.CAL† | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF† | Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB† | Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE† | XBRL Taxonomy Extension Presentation Linkbase Document |
104 | Cover Page Interactive Data File - this data file does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document. |

42

† Exhibits filed herein. All exhibits not so designated are incorporated by reference to a prior filing, as indicated.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| 3D Systems Corporation
| By | /s/ Michael Turner
|  | Michael Turner
|  | Executive Vice President and Chief Financial Officer
|  | (principal financial and accounting officer)

Date: May 10, 2023
43